

MULLANEY
EXHIBIT 44

From: "Brian Mullaney"
Subject: Re: Introduction
Sent: Thu, 30 May 2013 15:41:50 -0400
[image001.png](#)

From: Brian Mullaney [brian@wonderwork.org]
Sent: Thursday, May 30, 2013 11:42 AM
To: Hudner, Jim
CC: Ted Dysart
Subject: Re: Introduction

Hi Jim,

Thanks for the call yesterday.

I am sorry to make this more work than your usual assignment but the circumstances are very different.

I really do not feel that we will find any "traditional" or "aspirational" peer charities that are growing anywhere near as fast as we are or have the same caliber team. It is unfair and misleading to compare us to decades old charities that have stabilized at whatever level of revenues when we are growing at such a meteoric speed....I believe it is a waste of time for you to continue searching for peer charities or peer managements teams. You will not find them.

Most if not all the charities you have chosen are old, slow growing, stable, small, unimpressive, struggling, etc. in no respect are they a valid "peer" to WonderWork. Not even close.

WonderWork is growing much faster than Smile Train did which is our only really valid peer organization and our business plan is to create 5 Smile Trains, 5 \$100,000,000+ a year in revenue non-profits. No one has ever attempted this much less accomplished it. We are off to an impressive start.

Year Cash raised

2011 \$150,000

2012 \$8,000,000

2013 \$15,000,000

2014 \$30,000,000 - we do not have an approved budget for 2013 yet but this may very well be our target. Won't know this until our June board meeting. We cannot really do 5 year forecasts at this time because our history is short and it is impossible to accurately predict our growth outside of 12 months. Certainly our intent is to build a much larger organization than Smile Train.

In addition, doing a traditional comp review is not useful as it will be obsolete in a year when the size of the organization dramatically changes which brings up a very important point. My comp if it is tied to meteoric growth - which I think/hope it should/will be - needs to be reviewed on a yearly basis because if for some reason our growth slows, my comp may or may not be fair and reasonable. This also applies to my staff who I am paying at or near Smile Train levels because we are growing even faster than Smile Train and will end up as much larger organization and in fact, we are creating and building 4 charities - not one: WonderWork, BurnRescue, 1st Step and 20/20/20.

Finally, I am unique - not a traditional, nonprofit executive in any way....

- I created Smile Train and increased revenues from \$200,000 A YEAR TO \$170,000,000 a year in less than a decade.
- I helped raised almost \$1 billion for Smile Train.
- I helped create one of the most cost-efficient and productive charities in the world - according to the New York times - with one of the lowest payrolls for a charity this size. Less than \$4 million.
- I helped acquire 2.7 million donors.
- I created, produced and distributed a documentary about clefts that won an Oscar.
- I wrote a book for Smile Train which earned a \$150,000 advance from Hyperion.
- I was the first foreigner to receive one of China's most prestigious awards called Soong Ching Ling Camphor Tree

EXHIBIT -44

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR

TransPerfect Legal

award in China

Instead of using your traditional methodology for this assignment I would respectfully request that you explain to our board why a traditional approach is not feasible for this assignment and recommend another approach that will reflect the unique circumstances that we face today and will face over the next few years and that we make this assignment with your firm not a traditional one time review but a yearly review to ensure that the comp for me and my team is fair and reasonable for the growth and results we are delivering. This will protect the board, the charity and me and my team.

I realize this may involve more work on your part and more expense for us but I believe strongly this is the only practical and reasonable approach for a situation in where there are no peer charities and no comparable management team. And I realize this may jeopardize our schedule which is okay. I will discuss with Ted.

Please let me know what you think.

Thanks,

Brian

Brian Mullaney
Co-Founder/CEO
WonderWork *(formerly Surgery For The Poor)*
420 Fifth Avenue, 27th Floor
New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

From: <Hudner>, Jim <jim.hudner@pearlmeyer.com>
Date: Wednesday, May 22, 2013 7:26 AM
To: brian mullaney <brian@wonderwork.org>
Subject: RE: Introduction

Brian – Thanks for taking the time to speak with me yesterday. It was helpful context for me. You mentioned you had a document or two (strategic plan?) that you were going to forward along. If you could do so, that would be helpful.

Thanks

Jim

Jim Hudner
Managing Director

Pearl Meyer & Partners

WW_EMAILS0227453

Comprehensive Compensation

132 Turnpike Road, Suite 300

Southborough, MA 01772

508-460-9600 main, ext. 26-485 VoIP

508-630-1485 direct

508-460-9601 fax

jim.hudner@pearlmeyer.com

www.pearlmeyer.com

This email (and any attachments) was not intended or written to be used, and cannot be used, by you or any other person, for the purpose of (1) avoiding any penalties that may be imposed by the Internal Revenue Code, or (2) promoting, marketing or recommending to another party any transaction or other matter addressed herein, and the taxpayer should seek advice based on the taxpayer's particular circumstances from an independent tax advisor.

This is a transmission from Pearl Meyer & Partners, and may contain information that is privileged and confidential. Pearl Meyer & Partners assumes no responsibility for damages resulting from unauthorized access, disclosure or tampering, which could have occurred during transmission. If you have received this transmission in error, please destroy it and notify Pearl Meyer & Partners immediately at 212-644-2300.

From: Brian Mullaney [<mailto:brian@wonderwork.org>]

Sent: Monday, May 20, 2013 2:30 PM

To: Hudner, Jim

Subject: Re: Introduction

Hi Jim,

Nice to meet you.

Sure, how about 2:00 tomorrow?

B.

Brian Mullaney

Co-Founder/CEO

WonderWork

420 Fifth Avenue, 27th Floor


New York, NY 10018

tel: 212.729.1855

cell: 917.902.7550

email: brian@wonderwork.org

www.WonderWork.org



TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."

From: <Hudner>, Jim <jim.hudner@pearlmeyer.com>
Date: Monday, May 20, 2013 12:45 PM
To: Brian Mullaney <brian@wonderwork.org>
Subject: RE: Introduction

Brian – I look forward to speaking with you. Please let me know if you might have 20 – 30 minutes to speak during the following:

Tuesday – 10:00 – 4:00
Wednesday – 9:00 – 11:00

Thanks,

Jim Hudner
Managing Director

Pearl Meyer & Partners
Comprehensive Compensation
132 Turnpike Road, Suite 300
Southborough, MA 01772
508-460-9600 main, ext. 26-485 VoIP
508-630-1485 direct
508-460-9601 fax
jim.hudner@pearlmeyer.com
www.pearlmeyer.com

This email (and any attachments) was not intended or written to be used, and cannot be used, by you or any other person, for the purpose of (1) avoiding any penalties that may be imposed by the Internal Revenue Code, or (2) promoting, marketing or recommending to another party any transaction or other matter addressed herein, and the taxpayer should seek advice based on the taxpayer's particular circumstances from an independent tax advisor.

This is a transmission from Pearl Meyer & Partners, and may contain information that is privileged and confidential. Pearl Meyer & Partners assumes no responsibility for damages resulting from unauthorized access, disclosure or tampering, which could have occurred during transmission. If you have received this transmission in error, please destroy it and notify Pearl Meyer & Partners immediately at 212-644-2300.

From: Dysart, Ted [<mailto:tdysart@heidrick.com>]
Sent: Monday, May 20, 2013 12:21 PM
To: Brian Mullaney (brian@wonderwork.org)
Cc: Hudner, Jim
Subject: Introduction

Brian, meet Jim. Jim, meet Brian.

Brian, Jim is working with Pete on our engagement. We're trying to setup the peer groups for our compensation study. Jim and I thought it would be helpful for the two of you to chat. I leave it to the two of you to take it from here.

VVV_EMAILS0227453

Ted.

Theodore L. Dysart
Vice Chairman

Heidrick & Struggles

233 S. Wacker Drive

Chicago, IL 60606

tel: +1 (312) 496-1860

mobile: +1 (312) 638-9243

asst: Jackie Cahill +1 (312) 496-1751

tdysart@heidrick.com

follow me on twitter [@tldysart](#) or

Join me on [LinkedIn](#)

<http://www.theodoredysart.com>

MULLANEY
EXHIBIT 45

From: "Brian Mullaney"
Subject: Re: Pearl Meyer Study
Sent: Mon, 10 Jun 2013 13:50:42 -0400
[9EF6BCD9-0174-4326-9B6D-8273A602E8FC\[1\].png](#)

From: Brian Mullaney [brian@wonderwork.org]
Sent: Monday, June 10, 2013 9:51 AM
To: Dysart, Ted
Subject: Re: Pearl Meyer Study

Hi Ted,

Thanks.

I assume this is a DRAFT and I am allowed to give you feedback to correct some things and improve it.

Please omit slide 4 as it is inaccurate and misleading. I never formally requested this amount bonus. What I recommended is that we pay all of our Smile Train staff their former compensation as soon as we can afford it as they are a high performing team and these pay packages were all vetted and approved at Smile Train. These numbers reflect my pay package at Smile Train – which was reviewed by a compensation expert and approved – and since my performance at WonderWork is similar or even better, I thought same pay could be justified. He doesn't even mention this.

I don't think you need the A+ stuff, etc. and agree it is confusing.

I am okay with board deciding bonus annually on subjective judgement of performance.

I think that they should discuss that our senior management team is from Smile Train and note some of our/my accomplishments there....

Raised \$750 million in less than 10 years, one of the fattest growing charities in history, well managed and well respected.

Shouldn't we note performance at WonderWork someplace too? While we explain peer groups don't help much we don't reference anything else.

How about WonderWork growth EXCEEDING Smile Train growth?

Year 1 \$150,000
Year 2 \$8,000,000
Year 3 \$15,000,000
Year 4 \$25,000,000?

How about discussing our compensation philosophy of having a much smaller headcount of more senior people (i.e. Higher salaries) resulting overall in a much lower payroll for the organization? If you compare headcount and total payroll costs for any of these "peer" organizations, you will see that we are saving WonderWork MILLIONS of dollars. Shouldn't that at least be mentioned and or included?

WonderWork has 9 employees and we have raised \$20,000,000+ in our first three years.

How about mentioning that I am wearing many hats – CEO, Chief Development Officer, Chief Marketing Officer, etc. and that I write and produce much of our direct mail?

Please let me know what changes/improvements can be made to this every important document before it is finalized – perhaps we discuss and final after the meeting also?

Thanks for your help,

Brian

EXHIBIT -45

Brian Mullaney

8/17/17

S. Anelle Santos, RPR, CSR
TransPerfect Legal

Brian Mullaney
Co-Founder/CEO
WonderWork
420 Fifth Avenue, 27th Floor

WW_EMAILS0211672

New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org



TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."

From: <Dysart>, Ted Dysart <tdysart@heidrick.com>
Date: Monday, June 10, 2013 8:52 AM
To: "jjconeys@gmail.com" <jjconeys@gmail.com>, "ravikant@tatamotors.com" <ravikant@tatamotors.com>
Cc: Brian Mullaney <brian@wonderwork.org>
Subject: Pearl Meyer Study

JJ, Ravi & Brian,

Attached is the work product from Pearl Meyer & Partners in advance of our board meeting on Thursday. Our partners from Pearl Meyer will dial in to the meeting on Thursday to take us through all of this and answer any questions we may have.

Brian, I will text you the password. JJ & Ravi, I will e-mail it to you in a separate e-mail.

Ted.

Theodore L. Dysart
Vice Chairman

Heidrick & Struggles
233 S. Wacker Drive
Chicago, IL 60606
tel: +1 (312) 496-1860
mobile: +1 (312) 638-9243
asst: Jackie Cahill +1 (312) 496-1751
tdysart@heidrick.com
follow me on twitter [@tldysart](https://twitter.com/tldysart) or
Join me on [LinkedIn](#)
<http://www.theodoredysart.com>

MULLANEY
EXHIBIT 46

Miracle surgeries for children.

WonderWork

"A surgery that can change a child's life is one of the best investments anyone can make." —Warren Buffett
WonderWork Supporter

"...one of 10 ideas that will change the world."
—TIME

BOARD OF DIRECTORS & ADVISORY BOARD

Brian Mullaney
Co-Founder & CEO,
WonderWork

Steven D. Levitt
Author, *Freakonomics*

John (JJ) Coney
Former Vice Chair, PwC

Ravi Kant
Former Vice Chair, Tata Motors

Clark Kokich
Executive Chairman, Marchex

Steven Rappaport
Partner, RZ Capital

Richard Steele
Principal, SYPartners

Richard Prios
Chief Executive, Asia Pacific,
CBRE Global Investors

Mark Atkinson
Creative Director, Otto

Tamsen Ann Ziff
Chairman, Metropolitan Opera

Kenneth French
Tuck School at Dartmouth

Garrett Moran
President, Year Up

SUPPORTERS

Bryan Cranston
Actor

Christie Brinkley
Actor/Model

Howie Mandel
Comedian

Mariska Hargitay
Actor

Alex Trebek
Host of Jeopardy!

Bette Midler
Entertainer

Chris Meloni
Actor

Candice Bergen
Actor

Jane Kaczmarek
Actor

Sir Ben Kingsley
Actor



October 19, 2016

Dear Karen,

When you send your donation to a charity, do you ever wonder if it will make any difference?

Here's a true story that shows the impact of your donations to us.

Priya was 9 years old and completely blind when I took this picture of her. I happened to be visiting a partner hospital in Bihar, India the day she and her dad arrived after traveling 100 miles. Her father told me Priya lost her eyesight at the age of 3. He knew a surgery could restore her eyesight, but he could never afford it. He makes less than \$1 a day.



For six years, he took Priya from hospital to hospital, begging them to help her. They said no. But one day, he saw an ad from one of our partner hospitals offering free eye surgery for the poor.



The surgery Priya waited six long years for took 15 minutes. Today, her vision is normal, she's back in school and looking forward to a normal, healthy and happy life.

Without your support, Priya would still be blind.

Without your support, 167,115 other children and adults we've helped so far would still be blind.

Unlike many charities that raise enormous amounts of money a year and have large surpluses of unused donations, we need each and every donation we can get. And the more donations we receive - the more surgeries we can provide. It is that simple.

Your support means the world to us.

And your donations are saving blind children and adults no one else will help.

With gratitude,

Brian Mullaney
Co-Founder
212-729-1855
brian@wonderwork.org

PLEASE KNOW HOW MUCH
WE APPRECIATE - AND NEED -
YOUR HELP.

P.S. I've included an envelope in case you have any feedback for us, suggestions, ideas, etc.

100% of all donations goes towards our free surgery programs.
A founding donor pays all admin and fundraising expenses.

411 Fifth Avenue, Suite 702, New York, NY 10018 T. 212.729.1855 WonderWork.org

EXHIBIT -46
Brian Mullaney
8/17/17
S. Anelle Santos, RPR, CSR
TransPerfect Legal

Miracle surgeries for children
**wonder
work**

411 Fifth Avenue, Suite 702
New York, NY 10016



FOREVER USA

Karen Lazarus
WonderWork
411 5th Ave
Ste 702
New York, NY 10016

100% of all donations goes
towards our free surgery programs.
A founding donor pays all admin
and fundraising expenses.

1001582237 0065



Miracle surgeries for children
**wonder
work**

411 Fifth Avenue, Suite 702
New York, NY 10016

Attn: Brian

MULLANEY
EXHIBIT 47

From: Brian Mullaney [brian@wonderwork.org]
Sent: Monday, November 30, 2015 10:31 AM
To: Ravi Kant
CC: jjconeys@gmail.com
Subject: Re: Matters arising

Thanks Ravi.

Ted never told me that all of you discussed and agreed upon this course of action. I wish he had.

For the most part, Ted kept me in the dark on how he was handling this matter. I was really surprised to hear that he was hiring or had hired these labor lawyers in Chicago and very concerned about the cost and the optics. I wanted to make sure that you and JJ were on board with this because I was not. When I asked Ted he told me he assumed you were. Maybe you had agreed to hiring outside counsel but had not know who he planned to hire and how much they would charge.

Anyhow, if you and JJ feel that we should use outside counsel to handle this matter than that is what we will do. I am sure we can find some lawyers in New York that can handle this for a reasonable price. I do recommend that we postpone this until we have some new board members. I have gone 4 years without an agreement, I can wait another few months. Our focus right now should be on strengthening our board.

I was disappointed to receive Ted's resignation letter and regret that he resigned and especially the way he did it. Over the past 20 years, I have worked with more than 30 members of the Smile Train and WonderWork Boards of directors, Board of Governors, Advisory Boards and Medical Advisory Boards. Ted is the first and only director I have ever had problems working with.

From the very beginning, Ted and I had very different views on just about every subject. I will send him a letter thanking him for all of his contributions and wish him well.

As we all agreed at our last meeting, I have approached and been in discussions with the new board prospects that were presented to the board. Overall, I have been getting a lot of very positive interest and enthusiasm about joining our board. By year's end, I would like to send you a short list of 5-6 candidates for our board that we can discuss and vote on at our February meeting.

This will allow 2 months - Jan - Feb - for you and JJ to do any due diligence you would like including meeting with and or speaking with any of these prospects. I know all of these candidates for many years and am very excited about their joining our board.

After they are nominated and voted on in February, these new directors can then attend our year-end June meeting. They will receive staggered terms so some will receive 1, 2 and 3 year terms.

Please let me know if you and JJ are okay with this plan.

If you want to have a phone call to discuss any of this please let me know and I'd be happy to arrange it.

Thank you for your help and support.

Brian

Brian Mullaney
Co-Founder/CEO

EXHIBIT -47

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR
TransPerfect Legal

WonderWork
420 Fifth Avenue, 27th Floor
New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

Watch two blind sisters see their mom for the first time! <<https://www.wonderwork.org/>>
More than 6,500,000 people have watched this heart-warming video so far. It was the #1 watched video on the National Geographic website for 2014.

TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."

On 11/30/15, 1:24 AM, "Ravi Kant" <rkant644@gmail.com> wrote:

>Dear Brian,
>I regret to be responding late to your various mails as I have been travelling extensively overseas and in India.
>First I wish to tell you that the decision to refer to an outside counsel was a collective one of the independent directors. This was in the interest of the individual and organisation following good practice of corporate governance . We had hoped that you will take this in the right spirit.
>You have also referred to my comments in the board meeting. My view was that your personal time was required more urgently and extensively for raising funds from high net worth individuals . Therefore you needed to have a strong person to take care of direct mail which has been going downhill for sometime .
>With regards,
>Ravi
>
>Sent from my iPad

MULLANEY
EXHIBIT 48

From: Brian Mullaney [brian@wonderwork.org]
Sent: Monday, November 30, 2015 1:21 PM
To: DeLois Greenwood; Hana Fuchs; Karen Lazarus
Subject: ted dysart

Hi,

Yesterday I received quite a snarky resignation letter from Ted Dysart. He was unhappy because I strenuously objected to the fact that he went ahead and hired a Chicago law firm with two lawyers making \$980 and \$675 an hour to handle my employment contract. He had a call with Ravi and JJ which I guess gave him authority to do that although he never told me until after the fact.

I think he was also unhappy about 1. We put in place by-laws which make him leave the board in a year or two and 2. He couldn't come on the trip with Bryan Cranston 3. I was proposing all these new board members.

Anyhow, I have five new board members that will be proposed and hopefully voted upon at our next board meeting in February. They are all very excited about joining our board and helping us.

B.

Brian
Mullaney
Co-Founder/CEO

WonderWork
420 Fifth Avenue, 27th Floor
New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

Watch two blind sisters see their mom for the first time!

More than 6,500,000 people have watched this heart-warming video so far. It was the #1 watched video on the National Geographic website for 2014.



TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."

EXHIBIT -48

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR
TransPerfect Legal

MULLANEY
EXHIBIT 49

From: Brian Mullaney [brian@wonderwork.org]
Sent: Wednesday, December 21, 2016 9:14 AM
To: Coneys, JJ
Subject: Re: Board update

Hi JJ,

First some good news.

Our lawyers are meeting with HMS lawyers today or tomorrow to discuss a settlement. Their lawyers said they think it would make sense. (bear in mind this may be another game.)

We are offering to pay the entire award - \$8.3 million - over four years in the form of grants for cataract surgeries. A settlement would save them millions in legal fees and eliminate the risk of us just closing down and leaving them with close to nothing. Stay tuned.

I understand exactly what you are saying and I greatly appreciate your staying on the board to help with the transition.

But could you please wait just a little bit? There could not be a worse time than right now.

At a time where we really need our board to stand with us, it looks like everyone is jumping ship. First Dickie Steele resigned. Then Ravi Kant resigned. We haven't heard a word from Sabrina, our only female member, and she works with Dickie so I am sure she is about to resign. If we add you to those three it would be almost half our board resigning which would really hurt our chances of convincing a bankruptcy judge that we are a viable organization worth saving.

After all, if you own board members don't believe in us why should anyone else?

Can you please postpone your resignation for a 2-3 months?

We should have a resolution by then, one way or another.

1. We may be able to reach a settlement.
2. If no settlement is possible, we can enter Chapter 11 and come back out. Since we have \$19 million in the bank, are having a robust, fall fundraising season, and have the willingness and ability to pay 100% of the award, I am confident we will come up with a plan that will get approved.
3. If for whatever reason, dissolving the organization makes more sense, we can do that too quickly. We are a very simple organization with little debt and 99% liquid.

One way or another, you can resign in 2-3 months.

I am very grateful for all of your help, support and wise advice over the past four years.

If you could just hang on while we get past this crisis it would help us a lot.

Please consider it and call me later when you have a moment to discuss.

Thanks

b

EXHIBIT -49

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR

TransPerfect Legal

Brian Mullaney
Co-Founder/CEO

WonderWork
411Fifth Avenue, Suite 702 **NEW ADDRESS!**
New York, NY 10016
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

Watch two blind sisters see their mom for the first time!

More than 15,000,000 people have watched this heart-warming video so far. It was the #1 watched video on the National Geographic website for more than a year.



TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."

From: "Coneys, JJ" <JJ.Coneys@nexteraenergy.com>
Date: Wednesday, December 21, 2016 at 8:56 AM
To: Brian Mullaney <brian@wonderwork.org>
Subject: RE: Board update

Brian,

Making the bankruptcy filing this week seems like the prudent course of action. While it's unfortunate that we were not able to secure the services of the bankruptcy law firm you were hoping to get, CLM should be able to handle this for us.

We need to speak about the board, in particular my continued involvement. As you know, when my board term ended this past June 30th, I was concerned about the constraints my full-time job in Florida has put on me in carrying out my responsibilities as a WonderWork board member. I indicated to you then that I was reluctant to agree to another term but I ultimately agreed to stay on for one more year to ease the transition to a new slate of board members, thinking that my time commitment would be relatively light. With the HMS crisis unfolding, more time, not less, is needed for all board members to help you and the company weather this difficult storm. I have not been able to make that time commitment and do not envision being able to make it in the coming months. It is comforting to see that several of the new board members have stepped up to provide counsel and assistance to you as this has unfolded. But as WonderWork enters this next phase, the transition to the new board has taken place and the time is now right for me to stand down. The new board members are well positioned to carry on without my involvement and have effectively been doing so for the past two months. Put simply, if I am unable to carry out my responsibilities as board member to the best of my abilities, I should not continue to serve on the board. Accordingly, I am resigning from the board with immediate effect.

I am proud of my association with WonderWork and have greatly enjoyed working with you and your team. I will remain a staunch supporter of the WonderWork mission. But I also believe that you and the full board will be better served with board members who are able to invest the time and energy needed at this critical time.

I will call you to discuss this.

Regards,

J. J.

From: Brian Mullaney [<mailto:brian@wonderwork.org>]

Sent: Tuesday, December 20, 2016 10:20 AM

To: Brian Mullaney; Coneys, JJ; Steve Levitt; Clark Kokich; Steve Rappaport; sclark@sypartners.com; Richard Price; Mark Atkinson; mark atkinson; Poehling, James C.

Cc: Ashley Mull; Abreu, Maria

Subject: Board update

CAUTION - EXTERNAL EMAIL

Hi,

Here is the latest.

It turns out our new bankruptcy law firm is unable to help us. With our bank accounts being frozen we were unable to come up with the retainer they required.

Thus, we have returned to our original firm., CLM,, which had been preparing to file our papers for Chapter 11 Bankruptcy Reorganization last week. They graciously took us back.

They will file on our behalf either tomorrow or Thursday at the latest. This should free up our bank accounts and let us continue to operate. It will also prevent HSM from doing anything to harm us.

Please know that there is a risk that HMS will reject any plan that we propose and pressure the judge to close us down.

We have four months to come up with a compelling, credible plan that will show how we can pay HMS most if not all of their award over 3-4 years in the form of grants for cataract surgeries while still supporting our partners, paying back 100% of our impact loans, etc.

I am confident we can do this.

CLM is reaching out to HMS once again to see if they will engage in any settlement talks.

We are revising our PR holding statement to reflect the Chapter 11 filing and I will circulate shortly.

Any questions or concerns please let me know.

I would recommend our next board call be in early January with our lawyers to discuss our reorganization plan and what issues and options there are.

Until then, thank you for your help and support during this difficult time.

Merry Christmas.

Brian

Brian Mullaney

Co-Founder/CEO

WonderWork
411Fifth Avenue, Suite 702 **NEW ADDRESS!**
New York, NY 10016
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

Watch two blind sisters see their mom for the first time!

More than 15,000,000 people have watched this heart-warming video so far. It was the #1 watched video on the National Geographic website for more than a year.



TIME magazine named WonderWork "One of 10 Ideas That Can Change The World."
ne named WonderWork "One Of 10 Ideas That Can Change The World."

MULLANEY
EXHIBIT 50

| Patient ID number (Enter unique patient ID number) | Patient Name | Age in years (Enter one age format only) | Gender (Enter "M" for male, "F" for female, "U" for unknown) | Diagnosis blindness (Enter one type of diagnosis from this list: "congenital cataract", "developmental cataract", "traumatic cataract", "age-related cataract", specify if other) | Date of diagnosis (YYYYMMDD) | Date of most recent surgery (YYYYMMDD) | Operated eye(s) (Enter "R" for right, enter "L" for left, enter "B" for bilateral) | Visual acuity scale (Enter visual acuity scale: "Snellen feet", "Snellen metric", "Decimal", "LogMAR", specify if other) | Pre-operative uncorrected right eye visual acuity (Enter uncorrected visual acuity in numeric format for visual acuity scale selected) | Pre-operative uncorrected left eye visual acuity (Enter uncorrected visual acuity in numeric format for visual acuity scale selected) | Post-operative uncorrected right eye visual acuity (Enter uncorrected visual acuity in numeric format for visual acuity scale selected) | Post-operative uncorrected left eye visual acuity (Enter uncorrected visual acuity in numeric format for visual acuity scale selected) | Presence of comorbidity or complication (Enter "1" if patient has comorbidity or complication) | Date of most recent post-operative visit (YYYYMMDD) |
|---|--------------|---|---|--|---------------------------------|---|---|---|---|--|--|---|---|--|
| 704475 | | 68 | M | age-related cataract | 14-Oct-15 | 23-Oct-15 | L | Snellen feet | 20/60 | 18 ft. | 20/60 | 20/60 | 1 | 5-Dec-15 |
| 434114 | | 60 | M | age-related cataract | 16-Sep-15 | 23-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 5-Dec-15 |
| 475359 | | 55 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/60 | 20/40 | 20/60 | 20/40 | 0 | 20-Nov-15 |
| 60844 | | 50 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/200 | 20/60 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 624207 | | 60 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 10 ft. | 20/60 | 20/100 | 20/60 | 1 | 12-Nov-15 |
| 696917 | | 60 | F | age-related cataract | 6-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/100 | 20/100 | 20/200 | 20/100 | 0 | 10-Nov-15 |
| 706069 | | 69 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | PL+ | 20/200 | 20/60 | 20/100 | 1 | 26-Nov-15 |
| 706073 | | 69 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | PL+ | 20/60 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 706074 | | 60 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/60 | 18 ft. | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 406075 | | 75 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 0.5 ft. | PL+ | 20/60 | 20/60 | 1 | 20-Nov-15 |
| 406077 | | 70 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 2 ft. | 2 ft. | 20/60 | 20/60 | 1 | 20-Nov-15 |
| 706082 | | 60 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 4 ft. | 20/60 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 706083 | | 59 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/200 | 10 ft. | 20/200 | 20/60 | 0 | 20-Nov-15 |
| 706084 | | 60 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 6 ft. | 6 ft. | 20/60 | 16 ft. | 1 | 20-Nov-15 |
| 706085 | | 70 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/100 | 2 ft. | 20/100 | 20/100 | 0 | 20-Nov-15 |
| 706091 | | 59 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 16 ft. | 20/40 | 20/40 | 20/40 | 1 | 20-Nov-15 |
| 706096 | | 65 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 10 ft. | 6 ft. | 10 ft. | 10 ft. | 0 | 20-Nov-15 |
| 706100 | | 59 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 3 ft. | 20/100 | 20/100 | 20/100 | 1 | 20-Nov-15 |
| 706101 | | 71 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 2 ft. | 3 ft. | 20/100 | 3 ft. | 0 | 20-Nov-15 |
| 706102 | | 74 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 18 ft. | 20/200 | 20/200 | 20/200 | 0 | 20-Nov-15 |
| 706103 | | 54 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 18 ft. | 20/200 | 20/60 | 20/200 | 0 | 20-Nov-15 |
| 706104 | | 65 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/100 | 20/200 | 20/200 | 20/60 | 0 | 20-Nov-15 |
| 706105 | | 45 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/200 | 10 ft. | 20/40 | 10 ft. | 0 | 20-Nov-15 |
| 706106 | | 63 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/200 | 20/60 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 706108 | | 60 | F | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 20/200 | 20/100 | 20/60 | 20/100 | 1 | 20-Nov-15 |
| 706112 | | 75 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/100 | 6 ft. | 20/100 | 20/100 | 1 | 20-Nov-15 |
| 706113 | | 80 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 6 ft. | 20/200 | 9 ft. | 20/200 | 1 | 20-Nov-15 |
| 706115 | | 64 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | L | Snellen feet | 20/60 | PL+ | 20/60 | 20/60 | 1 | 20-Nov-15 |
| 706120 | | 56 | M | age-related cataract | 8-Oct-15 | 9-Oct-15 | R | Snellen feet | 10 ft. | 20/60 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 406214 | | 58 | M | age-related cataract | 19-Oct-15 | 27-Oct-15 | R | Snellen feet | 7 ft. | 8 ft. | 10/200 | 11 ft. | 0 | 10-Dec-15 |
| 705269 | | 58 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 10 ft. | 10 ft. | 10 ft. | 10/30 | 0 | 17-Nov-15 |
| 706574 | | 80 | F | age-related cataract | 10-Oct-15 | 14-Oct-15 | L | Snellen feet | 10 ft. | 10 ft. | 10 ft. | 10/100 | 0 | 18-Nov-15 |
| 706724 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/200 | 10/200 | 20/200 | 20/100 | 0 | 18-Nov-15 |
| 406726 | | 55 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/100 | 20/60 | 0 | 17-Nov-15 |
| 707029 | | 65 | F | age-related cataract | 12-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/200 | 20/200 | 20/200 | 20/60 | 0 | 18-Nov-15 |
| 707064 | | 70 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/60 | PL+ | 20/60 | 10 ft. | 1 | 31-Oct-15 |
| 707196 | | 72 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 2 ft. | 1 ft. | 2 ft. | 20/200 | 0 | 20-Oct-15 |
| 707199 | | 67 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/100 | 20/40 | 20/40 | 20/40 | 1 | 16-Nov-15 |
| 407200 | | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/60 | 20/100 | 20/60 | 20/100 | 0 | 17-Nov-15 |
| 707202 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 3 ft. | 10/200 | 20/60 | 20/60 | 0 | 19-Nov-15 |
| 707204 | | 55 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/200 | 20/100 | 20/60 | 20/100 | 0 | 17-Nov-15 |
| 407205 | | 64 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 17-Nov-15 |
| 407206 | | 65 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 3 ft. | 20/60 | 20/60 | 20/60 | 0 | 19-Nov-15 |
| 707207 | | 45 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/100 | 20/100 | 20/100 | 20/60 | 0 | 18-Nov-15 |
| 707308 | | 60 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 1 ft. | 20/200 | 20/60 | 20/200 | 0 | 17-Nov-15 |
| 707316 | | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/100 | 20/200 | 20/100 | 20/60 | 0 | 17-Nov-15 |
| 707210 | | 65 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/100 | 20/60 | 20/60 | 20/60 | 0 | 17-Nov-15 |
| 707211 | | 75 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 19-Nov-15 |
| 707212 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/60 | PL+ | 20/60 | 10/40 | 0 | 19-Nov-15 |
| 707214 | | 35 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | PL+ | 20/60 | 20/30 | 20/40 | 0 | 19-Nov-15 |
| 707215 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/200 | 20/100 | 20/60 | 20/100 | 0 | 18-Nov-15 |
| 707216 | | 62 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | PL+ | 9 ft. | 20/60 | 11 ft. | 0 | 21-Oct-15 |
| 707317 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 1 ft. | 20/200 | 20/100 | 20/200 | 0 | 19-Nov-15 |
| 407218 | | 65 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/200 | 20/200 | 20/200 | 20/60 | 1 | 18-Nov-15 |
| 707319 | | 50 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 4 ft. | 10/200 | 20/60 | 20/200 | 1 | 28-Nov-15 |
| 707220 | | 60 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 10/200 | 20/60 | 20/60 | 20/60 | 1 | 18-Nov-15 |
| 407222 | | 70 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/200 | 10 ft. | 20/200 | 20/60 | 0 | 17-Nov-15 |
| 707224 | | 65 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/200 | 2 ft. | 20/200 | 20/60 | 0 | 18-Nov-15 |
| 707225 | | 46 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 7 ft. | 5 ft. | 7 ft. | 20/60 | 0 | 19-Nov-15 |
| 707227 | | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 6 ft. | 6 ft. | 20/60 | 6 ft. | 0 | 19-Nov-15 |
| 707228 | | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | PL+ | 20/40 | 20/100 | 20/40 | 0 | 19-Nov-15 |
| 707229 | | 65 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 3 ft. | 3 ft. | 20/60 | 2 ft. | 0 | 21-Oct-15 |
| 707231 | | 72 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/200 | 20/60 | 20/200 | 10/60 | 0 | 18-Nov-15 |
| 707233 | | 60 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 4 ft. | 4 ft. | 20/60 | 14 ft. | 0 | 19-Nov-15 |
| 707235 | | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 18-Nov-15 |
| 707236 | | 65 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/60 | 2 ft. | 20/60 | 20/100 | 0 | 19-Nov-15 |
| 707240 | | 65 | M | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 6 ft. | 6 ft. | 20/60 | 16 ft. | 0 | 17-Nov-15 |

EXHIBIT -50
 Brian Mullaney
 8/17/17
 S. Anelle Santos, RPR, CSR
 TransPerfect Legal

| | | | | | | | | | | | | | |
|--------|----|---|----------------------|-----------|-----------|---|--------------|---------|--------|--------|--------|---|-----------|
| 707241 | 60 | F | age-related cataract | 18-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/200 | 20/200 | 20/60 | 20/200 | 0 | 15-Oct-15 |
| 707042 | 70 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | PL+ | PL+ | 20/80 | PL+ | 1 | 19-Nov-15 |
| 707246 | 70 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | R | Snellen feet | 20/100 | 20/200 | 20/100 | 20/200 | 0 | 18-Nov-15 |
| 707247 | 50 | F | age-related cataract | 13-Oct-15 | 14-Oct-15 | L | Snellen feet | 20/60 | 20/60 | PL+ | 20/100 | 0 | 19-Nov-15 |
| 512181 | 62 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/40 | 20/40 | 20/40 | 20/60 | 1 | 10-Oct-15 |
| 512283 | 55 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/40 | 20/40 | 20/40 | 20/40 | 0 | 10-Oct-15 |
| 521581 | 67 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 10-Oct-15 |
| 540970 | 65 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 12 ft. | 20/60 | 20/60 | 20/60 | 0 | 10-Oct-15 |
| 505503 | 70 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 595327 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/200 | 1 | 9-Nov-15 |
| 587144 | 50 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/40 | 20/40 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 639631 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 708100 | 59 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | HIM+ | 20/200 | 20/200 | 20/200 | 0 | 20-Oct-15 |
| 708101 | 70 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/200 | 20/100 | 20/200 | 20/30 | 0 | 20-Oct-15 |
| 708102 | 60 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 0.5 ft. | 20/200 | 20/200 | 20/40 | 0 | 10-Oct-15 |
| 708103 | 64 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | PL+ | 10 ft. | 20/60 | 10 ft. | 1 | 10-Oct-15 |
| 708104 | 60 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20/200 | 20/60 | 20 ft. | 0 | 10-Oct-15 |
| 708105 | 62 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/100 | 20/100 | 20/100 | 20/200 | 0 | 20-Oct-15 |
| 708106 | 72 | F | age-related cataract | 18-Oct-15 | 20-Oct-15 | L | Snellen feet | 15 ft. | 20 ft. | 15 ft. | 20/200 | 0 | 6-Nov-15 |
| 708107 | 74 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 708108 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/100 | 20/60 | 20/40 | 20/60 | 0 | 20-Oct-15 |
| 708111 | 58 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/40 | 20/100 | 20/40 | 15 ft. | 0 | 10-Oct-15 |
| 708112 | 54 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/40 | 20/60 | 0 | 10-Oct-15 |
| 708113 | 70 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20/60 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 708116 | 52 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/100 | 20/60 | 20/30 | 20/60 | 0 | 10-Oct-15 |
| 708117 | 66 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 15 ft. | 20/100 | 20/60 | 20/100 | 1 | 3-Dec-15 |
| 708118 | 50 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20 ft. | 20 ft. | 20 ft. | 20/60 | 0 | 10-Oct-15 |
| 708119 | 72 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 15 ft. | 20/60 | 20/60 | 20/60 | 1 | 10-Oct-15 |
| 708121 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20/60 | 20/60 | 20 ft. | 0 | 10-Oct-15 |
| 708122 | 60 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 10 ft. | 20/60 | 20/60 | 10 ft. | 0 | 20-Oct-15 |
| 708123 | 70 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20 ft. | 20/60 | 20 ft. | 20 ft. | 0 | 10-Oct-15 |
| 708126 | 54 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/60 | 20/40 | 20/60 | 20/40 | 0 | 20-Oct-15 |
| 708126 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20 ft. | 20/40 | 20 ft. | 0 | 20-Oct-15 |
| 708127 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 10 ft. | 20 ft. | 20/60 | 20 ft. | 0 | 20-Oct-15 |
| 708128 | 70 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/100 | PL+ | 20/100 | 20/60 | 0 | 10-Oct-15 |
| 708130 | 70 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/100 | 20/100 | 20/100 | 20/60 | 0 | 20-Oct-15 |
| 708132 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20 ft. | 20/200 | 20 ft. | 0 | 20-Oct-15 |
| 708132 | 70 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | HIM+ | 20/60 | 20 ft. | 0 | 20-Oct-15 |
| 708134 | 74 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/200 | 20/200 | 20/200 | 20/60 | 1 | 20-Oct-15 |
| 708135 | 58 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 10 ft. | 10 ft. | 20/60 | 10 ft. | 0 | 20-Oct-15 |
| 708136 | 60 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20/100 | 20/60 | 20/100 | 0 | 10-Oct-15 |
| 708139 | 70 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | HIM+ | 20 ft. | 20/60 | 20 ft. | 0 | 20-Oct-15 |
| 708140 | 68 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/100 | 20/60 | 20/100 | 20/200 | 0 | 20-Oct-15 |
| 708143 | 65 | M | age-related cataract | 18-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 708143 | 48 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/60 | 20/40 | 0 | 20-Oct-15 |
| 708144 | 63 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20 ft. | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 708145 | 57 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/30 | 19 ft. | 20/30 | 20/30 | 0 | 10-Oct-15 |
| 708146 | 52 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 10 ft. | 20/100 | 20/60 | 20/100 | 0 | 20-Oct-15 |
| 708148 | 55 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/60 | 20/100 | 20/60 | 20/100 | 1 | 27-Nov-15 |
| 708150 | 45 | F | age-related cataract | 18-Oct-15 | 19-Oct-15 | L | Snellen feet | 20/40 | HIM+ | 20/40 | 20/60 | 1 | 20-Oct-15 |
| 708151 | 65 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20 ft. | 20/60 | 20/60 | 20/60 | 0 | 20-Oct-15 |
| 708171 | 60 | M | age-related cataract | 18-Oct-15 | 19-Oct-15 | R | Snellen feet | 20/200 | 20/200 | 20/60 | 20/200 | 0 | 20-Oct-15 |
| 588031 | 40 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/60 | 20/100 | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 656511 | 57 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 705401 | 80 | F | age-related cataract | 6-Oct-15 | 21-Oct-15 | R | Snellen feet | 20 ft. | 20 ft. | 20/100 | 20 ft. | 0 | 22-Oct-15 |
| 708605 | 75 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 10 ft. | 20/60 | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 708606 | 60 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20 ft. | PL+ | 20 ft. | 20/60 | 0 | 22-Oct-15 |
| 708606 | 63 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/200 | 20/60 | 20/100 | 20/60 | 0 | 22-Oct-15 |
| 708610 | 80 | F | age-related cataract | 20-Oct-15 | 23-Oct-15 | L | Snellen feet | 20/60 | 20/60 | PL+ | 20/60 | 0 | 24-Oct-15 |
| 708611 | 75 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/200 | 20/200 | 20/200 | 20/60 | 0 | 22-Oct-15 |
| 708614 | 50 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 1 | 3-Dec-15 |
| 708617 | 80 | M | age-related cataract | 20-Oct-15 | 23-Oct-15 | L | Snellen feet | 20/40 | HIM+ | 20/40 | 20/40 | 0 | 24-Oct-15 |
| 708618 | 65 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | R | Snellen feet | HIM+ | 20/60 | 20/60 | 20/60 | 0 | 21-Oct-15 |
| 708620 | 69 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/200 | 20/60 | 20/60 | 20/60 | 1 | 12-Oct-15 |
| 708622 | 65 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/30 | 10 ft. | 20/30 | 20/60 | 0 | 22-Oct-15 |
| 708622 | 55 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/60 | HIM+ | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 708622 | 75 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20 ft. | 20/40 | 20 ft. | 20/40 | 0 | 22-Oct-15 |
| 708629 | 60 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20 ft. | 20 ft. | 20 ft. | 20/60 | 0 | 23-Oct-15 |
| 708630 | 55 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/60 | 20 ft. | 20/60 | 20/60 | 0 | 23-Oct-15 |
| 708630 | 65 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/60 | 20/100 | 20/60 | 20/60 | 0 | 23-Oct-15 |
| 708632 | 60 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/30 | 20 ft. | 20/30 | 20/60 | 0 | 22-Oct-15 |
| 708633 | 54 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 22-Oct-15 |
| 708634 | 51 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/100 | 20/100 | 20/100 | 20/60 | 0 | 22-Oct-15 |
| 708634 | 55 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/60 | 20/60 | 20/40 | 20/60 | 0 | 22-Oct-15 |

| | | | | | | | | | | | | | | |
|--------|--|----|---|----------------------|-----------|-----------|---|--------------|--------|--------|--------|--------|---|-----------|
| 708607 | | 54 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/80 | 20/100 | 20/80 | 20/30 | 0 | 23-Oct-15 |
| 708609 | | 70 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/80 | 20/100 | 20/80 | 20/40 | 0 | 23-Oct-15 |
| 708640 | | 54 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/30 | 20/40 | 20/30 | 20/80 | 0 | 22-Oct-15 |
| 708641 | | 74 | F | age-related cataract | 20-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/30 | 20/40 | 20/30 | 20/60 | 0 | 23-Oct-15 |
| 708643 | | 49 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/40 | 20/60 | 20/60 | 20/30 | 0 | 22-Oct-15 |
| 708645 | | 69 | M | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/40 | 20/60 | 20/60 | 20/30 | 0 | 22-Oct-15 |
| 708646 | | 49 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | L | Snellen feet | 20/40 | 20/200 | 20/40 | 20/80 | 0 | 22-Oct-15 |
| 708648 | | 55 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/100 | 20/40 | 20/100 | 20/60 | 0 | 22-Oct-15 |
| 708650 | | 59 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/100 | 20/60 | 20/60 | 20/80 | 0 | 22-Oct-15 |
| 708651 | | 70 | F | age-related cataract | 20-Oct-15 | 21-Oct-15 | R | Snellen feet | 20/100 | 20/30 | 20/60 | 20/30 | 0 | 22-Oct-15 |
| 87961 | | 60 | F | age-related cataract | 21-Oct-15 | 20-Oct-15 | L | Snellen feet | 20/60 | 20/40 | 20/60 | 20/60 | 0 | 23-Oct-15 |
| 592587 | | 45 | F | age-related cataract | 21-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/40 | PL+ | 20/40 | 20/60 | 0 | 25-Oct-15 |
| 636064 | | 46 | F | age-related cataract | 21-Oct-15 | 22-Oct-15 | R | Snellen feet | 20/200 | 20/200 | 20/40 | 20/200 | 0 | 25-Dec-15 |
| 641308 | | 65 | F | age-related cataract | 21-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/100 | 20/200 | 20/100 | 20/100 | 0 | 23-Oct-15 |
| 701561 | | 60 | F | age-related cataract | 21-Oct-15 | 22-Oct-15 | R | Snellen feet | 20/40 | 20/200 | 20/200 | 20/200 | 0 | 24-Oct-15 |
| 705081 | | 75 | M | age-related cataract | 21-Oct-15 | 22-Oct-15 | R | Snellen feet | PL+ | 20/100 | 20/40 | 20/100 | 0 | 24-Oct-15 |
| 708731 | | 45 | M | age-related cataract | 21-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/80 | 20/40 | 20/80 | 20/60 | 0 | 23-Oct-15 |
| 708736 | | 55 | M | age-related cataract | 21-Oct-15 | 22-Oct-15 | L | Snellen feet | 20/80 | 20/80 | 20/80 | 20/80 | 0 | 24-Oct-15 |
| 708738 | | 60 | M | age-related cataract | 21-Oct-15 | 23-Oct-15 | R | Snellen feet | PL+ | 20/80 | 20/80 | 20/90 | 0 | 24-Oct-15 |
| 708749 | | 60 | F | age-related cataract | 21-Oct-15 | 23-Oct-15 | R | Snellen feet | 20/200 | 20/60 | 20/60 | 20/60 | 0 | 24-Oct-15 |
| 642796 | | 58 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 20/100 | 20/40 | 20/100 | 0 | 23-Oct-15 |
| 654433 | | 65 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | PL+ | 20/100 | 20/80 | 0 | 23-Oct-15 |
| 683618 | | 60 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | 20/40 | 20/200 | 20/100 | 0 | 23-Oct-15 |
| 696228 | | 55 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 15 ft. | PL+ | 20/80 | 0 | 23-Oct-15 |
| 703668 | | 50 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/200 | 12 ft. | 20/200 | 20/40 | 0 | 23-Oct-15 |
| 705606 | | 74 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 12 ft. | 20/200 | 20/60 | 20/200 | 0 | 23-Oct-15 |
| 707850 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 12 ft. | 20/200 | 20/100 | 20/100 | 0 | 23-Oct-15 |
| 708016 | | 55 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/40 | PL+ | 20/40 | 20/80 | 0 | 23-Oct-15 |
| 709013 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | 15 ft. | 20/100 | 20/80 | 0 | 23-Oct-15 |
| 709049 | | 55 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 18 ft. | 15 ft. | 18 ft. | 20/60 | 0 | 23-Oct-15 |
| 709312 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 7 ft. | 20/40 | 20/40 | 20/40 | 0 | 23-Oct-15 |
| 709631 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/300 | 20/80 | 20/100 | 20/80 | 1 | 23-Oct-15 |
| 709631 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 20/40 | 20/40 | 20/40 | 0 | 23-Oct-15 |
| 709633 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/60 | 20/40 | 20/80 | 20/100 | 0 | 23-Oct-15 |
| 709635 | | 42 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 20/40 | 20/40 | 20/40 | 0 | 23-Oct-15 |
| 709636 | | 62 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 20/100 | 20/80 | 20/100 | 0 | 23-Oct-15 |
| 709637 | | 70 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 20/40 | PL+ | 20/40 | 0 | 23-Oct-15 |
| 709639 | | 73 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 10 ft. | 20/80 | 10 ft. | 0 | 23-Oct-15 |
| 709640 | | 60 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 20/40 | 20/80 | 20/80 | 0 | 23-Oct-15 |
| 709641 | | 45 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | 20/40 | 20/100 | 20/200 | 1 | 23-Oct-15 |
| 709642 | | 50 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/200 | 20/100 | 20/80 | 20/100 | 0 | 23-Oct-15 |
| 709643 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 10 ft. | 20/40 | 20/80 | 20/80 | 0 | 23-Oct-15 |
| 709644 | | 56 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/80 | 15 ft. | 20/80 | 20/80 | 0 | 23-Oct-15 |
| 709646 | | 70 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | PL+ | 20/100 | 20/60 | 20/100 | 0 | 23-Oct-15 |
| 709647 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/40 | PL+ | 20/40 | 20/80 | 0 | 23-Oct-15 |
| 709648 | | 65 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | 15 ft. | 20/100 | 20/80 | 0 | 23-Oct-15 |
| 709649 | | 70 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | 15 ft. | 20/100 | 20/100 | 0 | 23-Oct-15 |
| 709650 | | 71 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 15 ft. | 15 ft. | 20/80 | 15 ft. | 0 | 23-Oct-15 |
| 709651 | | 50 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 18 ft. | 15 ft. | 18 ft. | 20/80 | 0 | 23-Oct-15 |
| 709652 | | 65 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 15 ft. | 20/80 | 20/60 | 20/80 | 0 | 23-Oct-15 |
| 709654 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | L | Snellen feet | 20/100 | PL+ | 20/100 | 20/80 | 0 | 23-Oct-15 |
| 709655 | | 60 | F | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 20/100 | 20/60 | 20/100 | 0 | 23-Oct-15 |
| 709656 | | 60 | M | age-related cataract | 27-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 15 ft. | 20/40 | 15 ft. | 0 | 23-Oct-15 |
| 709657 | | 60 | M | age-related cataract | 28-Oct-15 | 28-Oct-15 | R | Snellen feet | 20/40 | 5 ft. | 20/100 | 20/40 | 0 | 23-Oct-15 |
| 711204 | | 58 | M | age-related cataract | 4-Nov-15 | 17-Nov-15 | R | Snellen feet | 20/200 | 20/200 | 20/100 | 20/200 | 0 | 7-Dec-15 |
| 711394 | | 65 | M | age-related cataract | 5-Nov-15 | 6-Nov-15 | R | Snellen feet | 20/100 | 20/100 | 20/80 | 20/100 | 0 | 8-Dec-15 |
| 711405 | | 60 | F | age-related cataract | 5-Nov-15 | 24-Nov-15 | L | Snellen feet | 20/200 | 20/200 | 20/200 | 20/60 | 0 | 14-Dec-15 |
| 711406 | | 50 | F | age-related cataract | 5-Nov-15 | 24-Nov-15 | R | Snellen feet | 20/200 | 20/200 | 20/40 | 20/200 | 0 | 2-Dec-15 |
| 711408 | | 55 | M | age-related cataract | 5-Nov-15 | 25-Nov-15 | R | Snellen feet | 15 ft. | 20/100 | 20/100 | 20/100 | 0 | 8-Dec-15 |
| 712351 | | 60 | M | age-related cataract | 10-Nov-15 | 10-Nov-15 | L | Snellen feet | 20/80 | 6 ft. | 20/80 | 20/80 | 0 | 27-Nov-15 |
| 712457 | | 81 | M | age-related cataract | 11-Nov-15 | 26-Nov-15 | L | Snellen feet | 20/40 | 20/40 | 20/40 | 20/80 | 0 | 4-Dec-15 |
| 712492 | | 52 | M | age-related cataract | 11-Nov-15 | 12-Nov-15 | R | Snellen feet | 12 ft. | 15 ft. | 20/100 | 15 ft. | 0 | 20-Nov-15 |
| 712568 | | 50 | F | age-related cataract | 12-Nov-15 | 12-Nov-15 | L | Snellen feet | 20/60 | 20/200 | 20/60 | 20/60 | 0 | 20-Nov-15 |
| 623080 | | 70 | F | age-related cataract | 8-Nov-15 | 9-Nov-15 | L | Snellen feet | 20/80 | 20/100 | 20/80 | 20/80 | 0 | 10-Nov-15 |
| 710132 | | 66 | M | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/40 | 20/100 | 20/80 | 20/100 | 0 | 10-Nov-15 |
| 710310 | | 79 | M | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/200 | 20/100 | 20/80 | 20/100 | 0 | 10-Nov-15 |
| 711352 | | 80 | F | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/200 | 20/200 | 20/40 | 20/200 | 0 | 10-Nov-15 |
| 711893 | | 69 | M | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/100 | 20/100 | 20/40 | 20/100 | 0 | 10-Nov-15 |
| 711906 | | 65 | M | age-related cataract | 8-Nov-15 | 9-Nov-15 | L | Snellen feet | 20/60 | 20/200 | 20/60 | 20/40 | 0 | 10-Nov-15 |
| 711936 | | 70 | M | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/200 | 20/200 | 20/80 | 20/200 | 0 | 10-Nov-15 |
| 712163 | | 60 | F | age-related cataract | 8-Nov-15 | 9-Nov-15 | R | Snellen feet | 20/200 | 20/200 | 20/80 | 20/200 | 0 | 10-Nov-15 |
| 541648 | | 50 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/40 | 20/100 | 20/60 | 20/100 | 0 | 24-Nov-15 |
| 587881 | | 60 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/60 | 10 ft. | 20/80 | 20/100 | 0 | 24-Nov-15 |
| 713199 | | 55 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/60 | 20/40 | 20/60 | 20/60 | 0 | 24-Nov-15 |

| | | | | | | | | | | | | | | | | | | |
|--------|--|----|---|------------------------|-----------|-----------|---|--------------|---------|----|---------|----|--------|--------|---------|----|-----------|----------|
| 71200 | | 66 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20 | ft | 4 | ft | 20/80 | 4 | ft | 0 | 24-Nov-15 | |
| 713201 | | 55 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 16 | ft | 6 | ft | 20/60 | 16 | ft | 0 | 24-Nov-15 | |
| 713202 | | 80 | F | age-related cataract | 16-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/100 | | 1 | ft | 20/100 | 20/80 | | 0 | 24-Nov-15 | |
| 712203 | | 70 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/100 | | 20/100 | | 20/60 | 20/100 | | 0 | 24-Nov-15 | |
| 712204 | | 55 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/60 | | 20/200 | | 20/80 | 20/100 | | 0 | 24-Nov-15 | |
| 712206 | | 72 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/100 | | 20/100 | | 20/60 | 20/100 | | 0 | 24-Nov-15 | |
| 713207 | | 75 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/200 | | 20/200 | | 20/200 | 20/60 | | 0 | 24-Nov-15 | |
| 713208 | | 50 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/200 | | 20/200 | | 20/40 | 20/200 | | 0 | 24-Nov-15 | |
| 713209 | | 65 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/800 | | HM+ | | 20/100 | 20/100 | | 0 | 24-Nov-15 | |
| 713210 | | 60 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 5 | ft | 2 | ft | 5 | ft | 10 | ft | 0 | 2-Dec-15 |
| 713211 | | 50 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/30 | | 17 | ft | 20/30 | 20/60 | | 0 | 24-Nov-15 | |
| 713212 | | 63 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/80 | | 20 | ft | 20/80 | 20/80 | | 0 | 24-Nov-15 | |
| 713214 | | 65 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/200 | | 20/80 | | 20/80 | 20/80 | | 0 | 24-Nov-15 | |
| 713215 | | 64 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/100 | | 2 | ft | 20/100 | 20/80 | | 1 | 24-Nov-15 | |
| 713216 | | 73 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | HM+ | | 8 | ft | 20/100 | 8 | ft | 0 | 24-Nov-15 | |
| 713217 | | 60 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/60 | | 10 | ft | 20/60 | 20/60 | | 0 | 24-Nov-15 | |
| 713219 | | 65 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/80 | | HM+ | | 20/80 | 20/60 | | 0 | 24-Nov-15 | |
| 713220 | | 65 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/80 | | 20/200 | | 20/60 | 20/40 | | 0 | 24-Nov-15 | |
| 713221 | | 50 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | 20/100 | | 20/80 | | 20/80 | 20/80 | | 0 | 24-Nov-15 | |
| 713222 | | 67 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | L | Snellen feet | 20/60 | | 1 | ft | 20/60 | 20/80 | | 0 | 24-Nov-15 | |
| 713225 | | 60 | F | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | HM+ | | 20/30 | | 20/80 | 20/30 | | 0 | 24-Nov-15 | |
| 713226 | | 52 | F | age-related cataract | 16-Nov-15 | 16-Nov-15 | R | Snellen feet | 10 | ft | 20/100 | | 20/60 | 20/100 | | 1 | 24-Nov-15 | |
| 713227 | | 45 | M | age-related cataract | 15-Nov-15 | 16-Nov-15 | R | Snellen feet | PL+ | | 20/80 | | 20/200 | 20/80 | | 0 | 24-Nov-15 | |
| 704223 | | 65 | M | age-related cataract | 19-Nov-15 | 20-Nov-15 | L | Snellen feet | 20/80 | | 20/100 | | 20/80 | 20/80 | | 0 | 21-Dec-15 | |
| 713801 | | 74 | M | age-related cataract | 19-Nov-15 | 20-Nov-15 | R | Snellen feet | 20/200 | | 20/100 | | 20 | ft | 20/100 | 0 | 9-Dec-15 | |
| 628149 | | 60 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 4 | ft | HM+ | | 5 | ft | 20/80 | 0 | 1-Dec-15 | |
| 704250 | | 40 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 3 | ft | 10 | ft | 20/40 | 10 | ft | 0 | 1-Dec-15 | |
| 715415 | | 75 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/60 | | 0 | ft | 20/60 | 20/60 | | 0 | 1-Dec-15 | |
| 715450 | | 65 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 20/100 | | 20/200 | | 20/80 | 20/200 | | 0 | 1-Dec-15 | |
| 715452 | | 62 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/60 | | 10 | ft | 20/60 | 20/60 | | 1 | 1-Dec-15 | |
| 715453 | | 70 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/60 | | 3 | ft | 20/60 | 20/100 | | 1 | 1-Dec-15 | |
| 715455 | | 59 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 3 | ft | 20/60 | | 20/60 | 20/60 | | 0 | 1-Dec-15 | |
| 715456 | | 76 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/200 | | 5 | ft | 20/200 | 20/80 | | 0 | 1-Dec-15 | |
| 715457 | | 60 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/80 | | 5 | ft | 20/80 | 20/80 | | 0 | 1-Dec-15 | |
| 715458 | | 65 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 10 | ft | 20/80 | | 20/80 | 20/80 | | 0 | 1-Dec-15 | |
| 715459 | | 38 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 5 | ft | 10 | ft | 20/80 | 10 | ft | 0 | 1-Dec-15 | |
| 715460 | | 60 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 20/200 | | 20/200 | | 20/80 | 20/200 | | 0 | 1-Dec-15 | |
| 715461 | | 60 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/100 | | 5 | ft | 20/100 | 20/80 | | 0 | 1-Dec-15 | |
| 715462 | | 73 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 20/200 | | 20/200 | | 20/80 | 20/80 | | 0 | 1-Dec-15 | |
| 715463 | | 72 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 10 | ft | 20/200 | | 20/80 | 20/200 | | 0 | 1-Dec-15 | |
| 715464 | | 66 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | L | Snellen feet | 10 | ft | PL+ | | 10 | ft | 20/80 | 0 | 1-Dec-15 | |
| 715465 | | 52 | M | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 5 | ft | 5 | ft | 20/40 | 5 | ft | 0 | 1-Dec-15 | |
| 715466 | | 65 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 20/40 | | 20/40 | | 20/80 | 20/40 | | 0 | 1-Dec-15 | |
| 715467 | | 42 | F | age-related cataract | 29-Nov-15 | 30-Nov-15 | R | Snellen feet | 5 | ft | 10 | ft | 20/60 | 10 | ft | 0 | 1-Dec-15 | |
| 715467 | | 59 | M | age-related cataract | 21-Nov-15 | 24-Nov-15 | R | Snellen feet | 20/200 | | 20/80 | | 20/30 | 20/80 | | 0 | 2-Dec-15 | |
| 710507 | | 50 | F | age-related cataract | 31-Oct-15 | 10-Nov-15 | L | Snellen feet | HM+ | | HM+ | | 20/60 | 20/60 | | 0 | 18-Nov-15 | |
| 711338 | | 50 | F | age-related cataract | 4-Nov-15 | 10-Nov-15 | L | Snellen feet | PL+ | | 4 | ft | PL+ | 20/40 | | 0 | 18-Nov-15 | |
| 579327 | | 3 | M | developmental cataract | 14-Nov-15 | 20-Nov-15 | R | Snellen feet | FTLight | | FTLight | | 10 | ft | FTLight | 0 | 28-Nov-15 | |
| 706426 | | 65 | F | age-related cataract | 3-Nov-15 | 24-Nov-15 | L | Snellen feet | 20/200 | | 10 | ft | 20/200 | 20/200 | | 0 | 2-Dec-15 | |
| 701899 | | 63 | M | age-related cataract | 13-Nov-15 | 25-Nov-15 | L | Snellen feet | 20/200 | | 20/200 | | 20/80 | 20/80 | | 0 | 3-Dec-15 | |
| 424766 | | 50 | F | age-related cataract | 9-Nov-15 | 10-Nov-15 | R | Snellen feet | 20/100 | | 20/100 | | 20/80 | 20/100 | | 0 | 15-Dec-15 | |
| 642859 | | 60 | F | age-related cataract | 6-Nov-15 | 11-Nov-15 | R | Snellen feet | 20/200 | | 20/40 | | 20/100 | 20/40 | | 0 | 9-Dec-15 | |
| 710135 | | 65 | M | age-related cataract | 28-Oct-15 | 26-Nov-15 | R | Snellen feet | HM+ | | 20/40 | | 20/60 | 20/40 | | 1 | 4-Dec-15 | |
| 710732 | | 50 | F | age-related cataract | 2-Nov-15 | 10-Nov-15 | R | Snellen feet | PL+ | | 6 | ft | 20/100 | 6 | ft | 0 | 18-Nov-15 | |
| 710740 | | 50 | F | age-related cataract | 2-Nov-15 | 18-Nov-15 | R | Snellen feet | 9 | ft | 20/100 | | 20/80 | 20/100 | | 0 | 19-Nov-15 | |
| 710141 | | 65 | M | age-related cataract | 28-Oct-15 | 10-Nov-15 | L | Snellen feet | 20/200 | | 5 | ft | 20/200 | 20/100 | | 0 | 19-Nov-15 | |
| 712185 | | 50 | M | age-related cataract | 9-Nov-15 | 17-Nov-15 | L | Snellen feet | 8 | ft | 8 | ft | 8 | ft | 20/200 | 0 | 25-Nov-15 | |
| 712804 | | 50 | F | age-related cataract | 13-Nov-15 | 25-Nov-15 | L | Snellen feet | 20/100 | | 8 | ft | 20/100 | 20/80 | | 0 | 3-Dec-15 | |
| 714109 | | 60 | F | age-related cataract | 21-Nov-15 | 24-Nov-15 | L | Snellen feet | 8 | ft | HM+ | | 8 | ft | 10 | ft | 1 | 9-Dec-15 |
| 712686 | | 65 | M | age-related cataract | 13-Nov-15 | 18-Nov-15 | L | Snellen feet | 20/100 | | PL+ | | 20/100 | 20/80 | | 0 | 19-Nov-15 | |
| 699855 | | 60 | M | age-related cataract | 2-Nov-15 | 10-Nov-15 | R | Snellen feet | 8 | ft | 10 | ft | 20/80 | 10 | ft | 0 | 18-Nov-15 | |
| 713055 | | 80 | F | age-related cataract | 14-Nov-15 | 24-Nov-15 | L | Snellen feet | 20/60 | | 20/80 | | 20/60 | 20/80 | | 0 | 2-Dec-15 | |
| 712975 | | 70 | F | age-related cataract | 21-Nov-15 | 24-Nov-15 | L | Snellen feet | 20/100 | | PL+ | | 20/100 | 20/60 | | 1 | 3-Dec-15 | |
| 711910 | | 54 | M | age-related cataract | 7-Nov-15 | 17-Nov-15 | R | Snellen feet | 10 | ft | 20/60 | | 20/80 | 20/60 | | 0 | 2-Dec-15 | |
| 527914 | | 50 | F | age-related cataract | 27-Oct-15 | 13-Nov-15 | R | Snellen feet | HM+ | | 20/60 | | 20/60 | 20/60 | | 0 | 21-Nov-15 | |
| 707549 | | 45 | M | age-related cataract | 15-Oct-15 | 10-Nov-15 | L | Snellen feet | 20/60 | | 5 | ft | 20/80 | 20/80 | | 0 | 18-Nov-15 | |
| 710263 | | 70 | F | age-related cataract | 29-Oct-15 | 10-Nov-15 | R | Snellen feet | PL+ | | 1 | ft | 20/100 | 1 | ft | 0 | 7-Dec-15 | |
| 711056 | | 50 | F | age-related cataract | 12-Nov-15 | 13-Nov-15 | R | Snellen feet | PL+ | | 20/100 | | 20/40 | 20/100 | | 0 | 12-Dec-15 | |
| 713766 | | 70 | F | age-related cataract | 10-Nov-15 | 24-Nov-15 | R | Snellen feet | PL+ | | 20/100 | | 20/80 | 20/60 | | 0 | 3-Dec-15 | |
| 713060 | | 65 | M | age-related cataract | 24-Nov-15 | 25-Nov-15 | L | Snellen feet | 20/60 | | PL+ | | 20/60 | 20/200 | | 0 | 26-Nov-15 | |
| 530609 | | 65 | F | age-related cataract | 13-Nov-15 | 17-Nov-15 | R | Snellen feet | 20/80 | | 20/80 | | 20/80 | 20/80 | | 0 | 15-Nov-15 | |
| 673713 | | 55 | F | age-related cataract | 7-Nov-15 | 10-Nov-15 | L | Snellen feet | 20/100 | | 8 | ft | 20/100 | 20/80 | | 0 | 18-Nov-15 | |
| 676104 | | 55 | M | age-related cataract | 28-Oct-15 | 10-Nov-15 | L | Snellen feet | 20/60 | | HM+ | | 20/80 | 20/80 | | 0 | 11-Dec-15 | |
| 711682 | | 74 | F | age-related cataract | 6-Nov-15 | 24-Nov-15 | L | Snellen feet | 20/80 | | 20/100 | | 20/80 | 20/80 | | 1 | 7-Dec-15 | |

| | | | | | | | | | | | | | |
|---------|----|---|----------------------|-----------|-----------|---|--------------|--------|--------|--------|--------|---|-----------|
| 70864 | 59 | M | age-related cataract | 20-Oct-15 | 18-Nov-15 | R | Snelten feet | 20/80 | 20/200 | 20/200 | 20/200 | 0 | 3-Dec-15 |
| 70869 | 65 | M | age-related cataract | 10-Oct-15 | 18-Nov-15 | R | Snelten feet | 8 ft | 20/60 | 20/100 | 20/60 | 1 | 3-Dec-15 |
| 70953 | 67 | M | age-related cataract | 27-Oct-15 | 18-Nov-15 | R | Snelten feet | PL+ | 20/100 | 20/60 | 20/100 | 0 | 18-Nov-15 |
| 58247 | 60 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 8 ft | 20/40 | 20/80 | 20/40 | 1 | 04-Dec-15 |
| 60047 | 55 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/60 | 18 ft | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 606727 | 60 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/60 | 8 ft | 20/60 | 20/60 | 1 | 15-Dec-15 |
| 606628 | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snelten feet | 20/60 | 20/200 | 20/60 | 20/60 | 0 | 01-Jun-16 |
| 716031 | 62 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 20/60 | 10 ft | 20/60 | 1 | 04-Dec-15 |
| 716032 | 75 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 10 ft | 10 ft | 8 ft | 8 ft | 1 | 04-Dec-15 |
| 716033 | 80 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 10 ft | 20/200 | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 716035 | 65 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/60 | PL+ | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 716036 | 60 | F | age-related cataract | 05-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 10 ft | 20/60 | 10 ft | 0 | 04-Dec-15 |
| 716037 | 73 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 20/200 | 20/200 | 20/200 | 20/200 | 0 | 04-Dec-15 |
| 716041 | 68 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/200 | CFO | 20/200 | 20/60 | 0 | 04-Dec-15 |
| 716042 | 65 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 10 ft | 20/60 | 10 ft | 1 | 04-Dec-15 |
| 716043 | 71 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 10 ft | 8 ft | 10 ft | 20/60 | 0 | 04-Dec-15 |
| 716044 | 78 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 8 ft | 10 ft | 20/60 | 10 ft | 0 | 04-Dec-15 |
| 716046 | 65 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 716047 | 57 | M | age-related cataract | 01-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/100 | 18 ft | 20/100 | 20/30 | 0 | 04-Dec-15 |
| 716049 | 55 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 8 ft | 20/200 | 20/60 | 20/200 | 0 | 04-Dec-15 |
| 716050 | 72 | F | age-related cataract | 01-Dec-15 | 03-Dec-15 | R | Snelten feet | 20/60 | CFO | 20/60 | CFCF | 0 | 02-Dec-15 |
| 716051 | 50 | F | age-related cataract | 01-Dec-15 | 03-Dec-15 | L | Snelten feet | 10 ft | 12 ft | 10 ft | 20/60 | 0 | 04-Dec-15 |
| 716053 | 60 | M | age-related cataract | 01-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 20/60 | 20/40 | 20/60 | 0 | 04-Dec-15 |
| 716054 | 60 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 20/200 | 20/200 | 20/60 | 20/200 | 0 | 04-Dec-15 |
| 716055 | 70 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/60 | CFCF | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 716056 | 70 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 20/200 | 20/200 | 20/40 | 20/200 | 0 | 04-Dec-15 |
| 716058 | 60 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/100 | 8 ft | 20/100 | 20/40 | 1 | 04-Dec-15 |
| 716059 | 60 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/60 | 8 ft | 20/60 | 20/60 | 0 | 04-Dec-15 |
| 716060 | 76 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/200 | 10 ft | 20/200 | 20/60 | 0 | 04-Dec-15 |
| 716061 | 60 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | L | Snelten feet | 20/200 | PL+ | 20/200 | 20/200 | 1 | 04-Dec-15 |
| 716062 | 60 | M | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 10 ft | 8 ft | 10 ft | 1 | 04-Dec-15 |
| 716063 | 60 | F | age-related cataract | 02-Dec-15 | 03-Dec-15 | R | Snelten feet | 10 ft | 20/200 | 20/60 | 20/200 | 0 | 04-Dec-15 |
| 716140 | 60 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 8 ft | 20/200 | 20/60 | 20/200 | 0 | 15-Dec-15 |
| 716151 | 55 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/40 | 10 ft | 20/40 | 20/60 | 0 | 15-Dec-15 |
| 716162 | 70 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/60 | 3 ft | 20/100 | 20/60 | 0 | 15-Dec-15 |
| 716154 | 53 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 20/400 | 20/200 | 20/400 | 20/200 | 1 | 15-Dec-15 |
| 716155 | 52 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | PL+ | 20/200 | 20/60 | 20/200 | 1 | 15-Dec-15 |
| 716156 | 60 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/60 | 8 ft | 20/60 | 20/60 | 0 | 15-Dec-15 |
| 716157 | 60 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/40 | 8 ft | 20/40 | 20/60 | 0 | 15-Dec-15 |
| 716158 | 60 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 10 ft | 3 ft | 10 ft | 20/60 | 0 | 15-Dec-15 |
| 716159 | 65 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | PL+ | 20/60 | 20/60 | 20/60 | 0 | 15-Dec-15 |
| 716160 | 59 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/40 | PL+ | 20/40 | 20/60 | 0 | 15-Dec-15 |
| 716161 | 85 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 10 ft | 20/200 | 20/200 | 20/200 | 0 | 15-Dec-15 |
| 716162 | 65 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 10 ft | 8 ft | 20/100 | 8 ft | 0 | 15-Dec-15 |
| 716163 | 63 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/100 | 10 ft | 20/100 | 20/60 | 0 | 15-Dec-15 |
| 716164 | 63 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 18 ft | 20/200 | 20/60 | 20/200 | 0 | 15-Dec-15 |
| 716165 | 65 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/200 | 20/200 | 20/60 | 20/60 | 1 | 15-Dec-15 |
| 716166 | 62 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | 20/100 | PL+ | 20/100 | 20/60 | 0 | 15-Dec-15 |
| 716168 | 65 | M | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | PL+ | 10 ft | 20/60 | 10 ft | 0 | 15-Dec-15 |
| 716169 | 38 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | PL+ | PL+ | 20/60 | PL+ | 0 | 15-Dec-15 |
| 716170 | 65 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | L | Snelten feet | CFCF | 20/200 | PL+ | 20/200 | 0 | 05-Jan-16 |
| 716171 | 63 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 20/100 | 10 ft | 20/100 | 20/60 | 0 | 15-Dec-15 |
| 716172 | 60 | F | age-related cataract | 13-Dec-15 | 14-Dec-15 | R | Snelten feet | 10 ft | 20/40 | 20/60 | 20/40 | 0 | 15-Dec-15 |
| 716175 | 65 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/60 | 20/60 | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161761 | 70 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 20/200 | 20/60 | 20/200 | 0 | 18-Dec-15 |
| 7161762 | 80 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 8 ft | 20/60 | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161764 | 60 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 20/200 | 20/60 | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161765 | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 8 ft | 8 ft | 20/60 | 8 ft | 0 | 18-Dec-15 |
| 7161766 | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 20/200 | 20/100 | 20/200 | 20/100 | 0 | 18-Dec-15 |
| 7161767 | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/100 | 8 ft | 20/100 | 18 ft | 1 | 28-Dec-15 |
| 7161768 | 70 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/60 | 10 ft | 20/60 | 20/40 | 0 | 18-Dec-15 |
| 7161769 | 80 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/200 | 10 ft | 20/200 | 20/60 | 0 | 18-Dec-15 |
| 7161770 | 70 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 10 ft | 8 ft | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161771 | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 8 ft | 20/60 | 8 ft | 1 | 18-Dec-15 |
| 7161772 | 80 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 12 ft | 20/60 | 12 ft | 0 | 18-Dec-15 |
| 7161773 | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 8 ft | 20/60 | 8 ft | 0 | 18-Dec-15 |
| 7161774 | 70 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 20/200 | 20/100 | 20/200 | 0 | 18-Dec-15 |
| 7161775 | 65 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 10 ft | 20/60 | 20/60 | 20/60 | 1 | 18-Dec-15 |
| 7161776 | 65 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/60 | 10 ft | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161777 | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snelten feet | 20/200 | 20/60 | 20/40 | 20/40 | 0 | 18-Dec-15 |
| 7161778 | 60 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/200 | 18 ft | 20/200 | 20/40 | 0 | 18-Dec-15 |
| 7161780 | 70 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 20/40 | 20/200 | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 7161782 | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 10 ft | 10 ft | 10 ft | 20/60 | 0 | 18-Dec-15 |
| 7161783 | 80 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snelten feet | 10 ft | PL+ | 10 ft | PL+ | 0 | 18-Dec-15 |

| | | | | | | | | | | | | | |
|--------|--|----|---|----------------------|-----------|-----------|---|--------------|--------|--------|--------|---|-----------|
| 718784 | | 60 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 10 ft | 10 ft | 20/100 | 0 | 18-Dec-15 |
| 718785 | | 60 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/200 | 15 ft | 20/200 | 0 | 18-Dec-15 |
| 718786 | | 65 | F | age-related cataract | 16-Dec-15 | 31-Dec-15 | R | Snellen feet | 8 ft | 20/200 | 20/60 | 0 | 18-Dec-15 |
| 718787 | | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/100 | PL+ | 20/100 | 1 | 18-Dec-15 |
| 718788 | | 55 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | PL+ | 20/200 | 20/40 | 0 | 18-Dec-15 |
| 718789 | | 65 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snellen feet | CFOF | 20/60 | 20/60 | 0 | 18-Dec-15 |
| 718790 | | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snellen feet | 10 ft | 20/200 | 20/60 | 0 | 18-Dec-15 |
| 718792 | | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 5 ft | 15 ft | 20/60 | 0 | 18-Dec-15 |
| 718795 | | 75 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/200 | 15 ft | 20/200 | 0 | 18-Dec-15 |
| 718796 | | 60 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | R | Snellen feet | 1 ft | 10 ft | 20/60 | 0 | 18-Dec-15 |
| 718797 | | 65 | M | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 0 | 18-Dec-15 |
| 718798 | | 70 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/100 | 10 ft | 20/100 | 0 | 18-Dec-15 |
| 718799 | | 75 | F | age-related cataract | 16-Dec-15 | 17-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 0 | 18-Dec-15 |
| 718807 | | 67 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 20/200 | 20/40 | 20/80 | 0 | 29-Dec-15 |
| 718821 | | 65 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/80 | 15 ft | 20/80 | 0 | 29-Dec-15 |
| 718831 | | 67 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/200 | 15 ft | 20/200 | 0 | 29-Dec-15 |
| 720632 | | 60 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | PL+ | 20/80 | 20/80 | 0 | 29-Dec-15 |
| 720633 | | 60 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 0 | 29-Dec-15 |
| 720634 | | 50 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 10 ft | 20/400 | 20/400 | 0 | 29-Dec-15 |
| 720635 | | 45 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/80 | PL+ | 20/80 | 0 | 29-Dec-15 |
| 720637 | | 67 | M | age-related cataract | 28-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 1 | 29-Dec-15 |
| 720638 | | 65 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 15 ft | 15 ft | 20/60 | 0 | 29-Dec-15 |
| 720639 | | 60 | F | age-related cataract | 27-Dec-15 | 30-Dec-15 | R | Snellen feet | 3 ft | 10 ft | 15 ft | 1 | 29-Dec-15 |
| 720640 | | 50 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/200 | 15 ft | 20/200 | 0 | 29-Dec-15 |
| 720641 | | 62 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/100 | 15 ft | 20/100 | 0 | 29-Dec-15 |
| 720643 | | 70 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 10 ft | 12 ft | 20/40 | 0 | 29-Dec-15 |
| 720644 | | 65 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 20/200 | 20/60 | 20/100 | 0 | 29-Dec-15 |
| 720645 | | 75 | M | age-related cataract | 27-Dec-15 | 29-Dec-15 | R | Snellen feet | PL+ | 20/200 | 20/100 | 0 | 29-Dec-15 |
| 720646 | | 70 | M | age-related cataract | 27-Dec-15 | 29-Dec-15 | R | Snellen feet | CFOF | 10 ft | 20/80 | 0 | 29-Dec-15 |
| 720647 | | 65 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | 10 ft | 20/60 | 15 ft | 0 | 29-Dec-15 |
| 720648 | | 65 | F | age-related cataract | 27-Dec-15 | 29-Dec-15 | L | Snellen feet | 10 ft | 20/200 | 20/60 | 0 | 30-Dec-15 |
| 720649 | | 65 | F | age-related cataract | 27-Dec-15 | 29-Dec-15 | R | Snellen feet | 10 ft | 20/60 | 20/60 | 1 | 30-Dec-15 |
| 720650 | | 70 | M | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/60 | 10 ft | 20/60 | 1 | 30-Dec-15 |
| 720651 | | 65 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | PL+ | 10 ft | 10 ft | 1 | 29-Dec-15 |
| 720654 | | 50 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | R | Snellen feet | PL+ | 20/100 | 20/80 | 0 | 29-Dec-15 |
| 720655 | | 60 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/60 | PL+ | 20/60 | 0 | 29-Dec-15 |
| 720656 | | 80 | F | age-related cataract | 27-Dec-15 | 28-Dec-15 | L | Snellen feet | 20/60 | CFOF | 20/80 | 0 | 29-Dec-15 |
| 721169 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 5 ft | 20/60 | 20/60 | 0 | 01-Jan-16 |
| 721170 | | 45 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 20/40 | 20/60 | 0 | 01-Jan-16 |
| 721171 | | 65 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/200 | 20/200 | 20/80 | 0 | 01-Jan-16 |
| 721172 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/100 | 0 | 01-Jan-16 |
| 721173 | | 58 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/80 | 15 ft | 20/60 | 0 | 01-Jan-16 |
| 721174 | | 70 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721175 | | 65 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/60 | 10 ft | 20/80 | 0 | 01-Jan-16 |
| 721176 | | 57 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721177 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/80 | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721178 | | 50 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 2 ft | 20/100 | 20/80 | 0 | 01-Jan-16 |
| 721179 | | 70 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/60 | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721180 | | 67 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/80 | 0 | 01-Jan-16 |
| 721181 | | 72 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721182 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 0 | 01-Jan-16 |
| 721184 | | 75 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/80 | 0 | 01-Jan-16 |
| 721186 | | 50 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 15 ft | 15 ft | 20/80 | 0 | 01-Jan-16 |
| 721187 | | 65 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 20/100 | 20/60 | 20/100 | 0 | 01-Jan-16 |
| 721188 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/200 | 20/400 | 20/200 | 0 | 01-Jan-16 |
| 721189 | | 55 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 10 ft | 20/60 | 0 | 01-Jan-16 |
| 721190 | | 55 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 15 ft | 15 ft | 20/80 | 5 | 01-Jan-16 |
| 721192 | | 66 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 20/80 | 20/60 | 0 | 01-Jan-16 |
| 721193 | | 65 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 10 ft | 10 ft | 20/80 | 0 | 01-Jan-16 |
| 721194 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 15 ft | 20/80 | 20/100 | 0 | 01-Jan-16 |
| 721195 | | 65 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/80 | 15 ft | 20/80 | 0 | 01-Jan-16 |
| 721196 | | 57 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/200 | CFOF | 20/200 | 0 | 01-Jan-16 |
| 721198 | | 80 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/200 | 10 ft | 20/200 | 1 | 01-Jan-16 |
| 721199 | | 60 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 10 ft | 10 ft | 20/80 | 0 | 01-Jan-16 |
| 721200 | | 50 | F | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/200 | 20/400 | 20/200 | 0 | 01-Jan-16 |
| 721201 | | 80 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | R | Snellen feet | 10 ft | 15 ft | 20/80 | 0 | 01-Jan-16 |
| 721202 | | 60 | M | age-related cataract | 30-Dec-15 | 31-Dec-15 | L | Snellen feet | 20/60 | 15 ft | 20/60 | 0 | 01-Jan-16 |
| 636084 | | 45 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/40 | 20/200 | 20/60 | 0 | 10-Dec-15 |
| 657255 | | 80 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/80 | 20/200 | 20/60 | 1 | 10-Dec-15 |
| 717199 | | 60 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/200 | 20/600 | 20/200 | 0 | 17-Dec-15 |
| 717140 | | 63 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | R | Snellen feet | 20/100 | 20/100 | 20/100 | 0 | 10-Dec-15 |
| 717141 | | 60 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | R | Snellen feet | 17 ft | 20/30 | 20/60 | 0 | 10-Dec-15 |
| 717143 | | 70 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | R | Snellen feet | 18 ft | 20/200 | 20/80 | 0 | 10-Dec-15 |
| 717144 | | 80 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/100 | 20/100 | 20/100 | 0 | 10-Dec-15 |

| | | | | | | | | | | | | | |
|--------|----|---|--------------------------------------|-----------|-----------|---|--------------|---------|---------|---------|---------|---|-----------|
| 717146 | 68 | M | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/80 | 10 ft | 20/80 | 20/80 | 0 | 10-Dec-15 |
| 717150 | 70 | M | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/80 | 8 ft | 20/80 | HM+ | 1 | 10-Dec-15 |
| 717166 | 50 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | L | Snellen feet | 20/80 | HM+ | 20/80 | 20/200 | 1 | 10-Dec-15 |
| 717168 | 40 | F | age-related cataract | 08-Dec-15 | 09-Dec-15 | R | Snellen feet | 8 ft | 20/100 | 20/80 | 20/100 | 0 | 10-Dec-15 |
| 681276 | 1 | F | Congenital Cataract | 17-Jun-15 | 6-Aug-15 | R | Snellen feet | NC | NC | NC | NC | 0 | 5-Sep-15 |
| 632976 | 16 | M | Cataract, Post RD | 18-Jul-15 | 6-Aug-15 | R | Snellen feet | 0.5 ft | 20/20 | 1 ft | 20/20 | 0 | 7-Sep-15 |
| 687175 | 10 | M | Traumatic Cataract | 7-Jul-15 | 11-Aug-15 | R | Snellen feet | PL+ | 20/20 | HM+ | 20/20 | 0 | 28-Sep-15 |
| 687279 | 11 | M | Traumatic Cataract | 7-Jul-15 | 18-Aug-15 | L | Snellen feet | 20/20 | 0.5 ft | 20/20 | 20/200 | 0 | 29-Aug-15 |
| 695911 | 10 | M | Subluxation of lens | 18-Aug-15 | 20-Aug-15 | R | Snellen feet | 18 ft | 10 ft | 20/100 | 10 ft | 0 | 22-Sep-15 |
| 693384 | 15 | F | Developmental Cataract | 7-Aug-15 | 27-Aug-15 | R | Snellen feet | 20/80 | 20/60 | 20/80 | 20/80 | 0 | 28-Sep-15 |
| 645596 | M | M | Aphakia | 10-Aug-15 | 27-Aug-15 | R | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 21-Oct-15 |
| 667032 | 10 | F | Zonular Cataract | 30-Aug-15 | 2-Sep-15 | L | Snellen feet | 7 ft | 1.5 ft | 7 ft | 8 ft | 0 | 8-Oct-15 |
| 690702 | 6 | F | Developmental Cataract | 26-Aug-15 | 2-Sep-15 | R | Snellen feet | PL+ | 2 ft | 20/40 | 2 ft | 0 | 30-Nov-15 |
| 691827 | 9 | M | Developmental Cataract | 6-Aug-15 | 2-Sep-15 | L | Snellen feet | 20/80 | 20/30 | 20/80 | 20/80 | 0 | 3-Oct-15 |
| 696363 | 12 | M | Subluxation of lens, Ectopia Lentis | 2-Sep-15 | 7-Sep-15 | R | Snellen feet | 18 ft | 20/200 | 20/200 | 20/200 | 0 | 22-Oct-15 |
| 692838 | 11 | M | Mature Cataract | 7-Sep-15 | 9-Sep-15 | L | Snellen feet | 8 ft | HM+ | 8 ft | HM+ | 0 | 20-Oct-15 |
| 679761 | 5 | M | Developmental Cataract | 26-Aug-15 | 10-Sep-15 | R | Snellen feet | 25-100 | 20/80 | 20/40 | 20/80 | 1 | 10-Oct-15 |
| 395599 | 4 | M | Developmental Cataract | 8-Sep-15 | 16-Sep-15 | R | Snellen feet | HM+ | 20/200 | 8 ft | 20/200 | 0 | 15-Oct-15 |
| 655537 | M | M | Congenital Cataract | 10-Sep-15 | 16-Sep-15 | R | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 27-Oct-15 |
| 700572 | 5 | M | Isoli Cataract | 14-Sep-15 | 24-Sep-15 | R | Snellen feet | PR+ | 4 ft | 20/80 | 4 ft | 0 | 24-Oct-15 |
| 668799 | 16 | M | Post, Sub Capsular Cataract, Post RD | 25-Sep-15 | 30-Sep-15 | R | Snellen feet | 2 ft | 20/20 | 3 ft | 20/20 | 0 | 13-Nov-15 |
| 700580 | 8 | M | Cortical Cataract, Left Cornea | 14-Sep-15 | 20-Sep-15 | L | Snellen feet | 20/20 | 8 ft | 0 ft | 8 ft | 0 | 23-Nov-15 |
| 696630 | 2 | M | Traumatic Cataract | 2-Sep-15 | 2-Oct-15 | R | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 7-Nov-15 |
| 705045 | 19 | F | Zonular Cataract | 4-Oct-15 | 6-Oct-15 | R | Snellen feet | PL+ | PL+ | NC | PL+ | 0 | 9-Oct-15 |
| 700572 | 5 | M | Total Cataract | 1-Oct-15 | 6-Oct-15 | L | Snellen feet | 20/200 | 5 ft | 20/200 | 20/80 | 0 | 28-Nov-15 |
| 654809 | 10 | M | Bulbus Keratopathy, Post PK | 28-Sep-15 | 8-Oct-15 | L | Snellen feet | 20/20 | 0.5 ft | 20/20 | 3.5 ft | 1 | 16-Nov-15 |
| 554831 | 12 | M | Post Sili Capsular Cataract | 29-Sep-15 | 8-Oct-15 | L | Snellen feet | 20/30 | 20/60 | 20/30 | 20/40 | 0 | 7-Nov-15 |
| 683276 | 1 | F | Congenital Cataract | 5-Sep-15 | 12-Oct-15 | L | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 5-Dec-15 |
| 702648 | 16 | M | Scissural Cataract | 10-Sep-15 | 12-Oct-15 | L | Snellen feet | 20/80 | 20/80 | 20/80 | 20/40 | 0 | 21-Dec-15 |
| 645596 | 3 | M | Aphakia | 10-Sep-15 | 13-Oct-15 | L | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 14-Nov-15 |
| 704589 | 4 | M | Zonular Cataract | 2-Oct-15 | 12-Oct-15 | R | Snellen feet | PL+ | PL+ | 20/80 | PL+ | 0 | 18-Nov-15 |
| 705063 | 6 | M | Traumatic Cataract | 5-Oct-15 | 14-Oct-15 | L | Snellen feet | 2 ft | 2 ft | 2 ft | 8 ft | 0 | 24-Oct-15 |
| 694918 | 6 | M | Congenital Cataract | 11-Aug-15 | 20-Oct-15 | R | Snellen feet | 3 ft | 2 ft | 20/100 | 3 ft | 0 | 4-Dec-15 |
| 696510 | 7 | M | Zonular Cataract | 3-Sep-15 | 20-Oct-15 | L | Snellen feet | 20/60 | 20/100 | 20/60 | 20/100 | 0 | 20-Nov-15 |
| 655537 | M | M | Congenital Cataract | 17-Oct-15 | 27-Oct-15 | L | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 27-Nov-15 |
| 691066 | 10 | M | Aphakia | 25-Oct-15 | 28-Oct-15 | R | Snellen feet | 5 ft | 20/20 | 8 ft | 20/20 | 0 | 4-Nov-15 |
| 640126 | 1 | F | Aphakia | 22-Sep-15 | 3-Nov-15 | R | Snellen feet | FFLight | FFLight | FFLight | FFLight | 0 | 12-Nov-15 |
| 703227 | 14 | F | Post Sili Capsular Cataract | 14-Oct-15 | 4-Nov-15 | R | Snellen feet | 20/200 | 20/20 | 10 ft | 20/20 | 0 | 3-Dec-15 |
| 644313 | 15 | F | Spasmodic | 6-Nov-15 | 12-Nov-15 | L | Snellen feet | 10 ft | 10 ft | 20/20 | 20/20 | 1 | 16-Dec-15 |
| 694118 | 6 | M | Congenital Cataract | 10-Nov-15 | 26-Nov-15 | L | Snellen feet | 20/60 | 20/200 | 20/100 | 20/200 | 0 | 4-Dec-15 |

MULLANEY
EXHIBIT 51



April 15, 2013

KPMG LLP
345 Park Avenue
New York, NY 10154

Ladies and Gentlemen:

We are providing this letter in connection with your audit of the balance sheet of WonderWork, Inc. (the Organization) as of June 30, 2012, and the related statements of activities, functional expenses and cash flows for the year then ended, for the purpose of expressing an opinion as to whether these financial statements present fairly, in all material respects, the financial position of the Organization, and the changes in its net assets and its cash flows in conformity with U.S. generally accepted accounting principles.

Certain representations in this letter are described as being limited to matters that are material. Items are considered material, regardless of size, if they involve an omission or misstatement of accounting information that, in the light of surrounding circumstances, makes it probable that the judgment of a reasonable person relying on the information would be changed or influenced by the omission or misstatement.

We confirm, to the best of our knowledge and belief, the following representations made to you during your audit:

1. The financial statements referred to above are fairly presented in conformity with U.S. generally accepted accounting principles.
2. We have made available to you:
 - a. All financial records and related data.
 - b. All minutes of meetings of the Board of Directors and committees of the Board of Directors, or summaries of actions of recent meetings for which minutes have not yet been prepared.

TIME magazine named WonderWork one of "10 Ideas That Can Change The World."
420 Fifth Avenue, New York, NY 10018 Tel: 212.729.1821 WonderWork.org

EXHIBIT -51

Brian Mullaney

8/17/17

S. Anelle Santos, RPR, CSR
TransPerfect Legal

WON-EX 042016



3. Except as disclosed to you in writing, there have been no communications from regulatory agencies, employees, or others concerning investigations or allegations of noncompliance with laws and regulations in any jurisdiction, deficiencies in financial reporting practices, or other matters that could have a material adverse effect on the financial statements.
4. There are no:
 - a. Violations or possible violations of laws or regulations, whose effects should be considered for disclosure in the financial statements or as a basis for recording a loss contingency.
 - b. Unasserted claims or assessments that our lawyer has advised us are probable of assertion and must be disclosed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 450, *Contingencies*.
 - c. Other liabilities or gain or loss contingencies that are required to be accrued or disclosed by FASB ASC 450, *Contingencies*.
 - d. Material transactions that have not been properly recorded in the accounting records underlying the financial statements.
 - e. Events that have occurred subsequent to the balance sheet date and through the date of this letter that would require adjustment to or disclosure in the financial statements.
5. There were no uncorrected financial statement misstatements.
6. We acknowledge our responsibility for the design and implementation of programs and controls to prevent, deter, and detect fraud. We understand that the term "fraud" includes misstatements arising from fraudulent financial reporting and misstatements arising from misappropriation of assets.

Misstatements arising from fraudulent financial reporting are intentional misstatements, or omissions of amounts or disclosures in financial statements to deceive financial statement users. Misstatements arising from misappropriation of assets involve the theft of an entity's assets where the effect of the theft causes the financial statements not to be presented in conformity with U.S. generally accepted accounting principles.

7. We have no knowledge of any fraud or suspected fraud affecting the entity involving:



- a. Management
 - b. Employees who have significant roles in internal control over financial reporting, or
 - c. Others where the fraud could have a material effect on the financial statements.
8. We have no knowledge of any allegations of fraud or suspected fraud affecting the entity received in communications from employees, former employees, regulators, or others.
 9. The Organization has no plans or intentions that may materially affect the carrying value or classification of assets and liabilities.
 10. We have no knowledge of any officer or director of the Organization, or any other person acting under the direction thereof, having taken any action to fraudulently influence, coerce, manipulate, or mislead you during your audit.
 11. The following have been properly recorded or disclosed in the financial statements, if applicable:
 - a. Related party transactions including sales, purchases, loans, transfers, leasing arrangements, guarantees, ongoing contractual commitments, and amounts receivable from or payable to related parties.

The term "related party" refers to affiliates of the enterprise; entities for which investments in their equity securities would, absent the election of the fair value option under FASB ASC 825, Financial Instruments, be required to be accounted for by the equity method by the enterprise; trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; principal owners of the enterprise; its management; members of the immediate families of principal owners of the enterprise and its management; and other parties with which the enterprise may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Another party also is a related party if it can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.



- b. Guarantees, whether written or oral, under which the Organization is contingently liable, including guarantee contracts and indemnification agreements pursuant to FASB ASC 460, *Guarantees*.
- c. Significant estimates and material concentrations known to management that are required to be disclosed in accordance with FASB ASC 275, *Risks and Uncertainties*.

Significant estimates are estimates at the balance sheet date, which could change materially within the next year. Concentrations refer to volumes of business, revenues, available sources of supply, or markets or geographic areas for which it is reasonably possible that events could occur which would significantly disrupt normal finances within the next year.

- 12. The Organization has satisfactory title to all owned assets, and there are no liens or encumbrances on such assets, nor has any asset been pledged as collateral.
- 13. The Organization has complied with all aspects of laws, regulations, contracts, grants, and donor restrictions that would have a material effect on the financial statements in the event of noncompliance.
- 14. The Organization has been recognized as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code of 1986 as an organization described in Section 501(c)(3) of the Code, as evidenced by our determination letter dated September 11, 2012, a copy of which has been furnished to you. Since the date of our determination letter, no changes have occurred in the organization or operation of the Organization that would affect our tax exempt status. Based on our determination letter, we have been classified as a public charity under Section 509(a) of the Internal Revenue Code, and since the date of our determination letter, no changes have occurred in the organization or its operations that would change this classification. Provision has been made, where material, for any federal, state or local income, excise, employment, property, sales and use, or other tax liability.
- 15. The Organization has classified net assets as unrestricted, temporarily restricted or permanently restricted based on our assessment of the donor's intention, as specified in original donor correspondence where available. Where not available, we used other corroborating evidential matter including minutes of the Board, accounting records and financial statements. To the extent that we were unable to review original donor correspondence to determine the amount of the original gift and donor additions, our determination of such amount was based on our best estimate considering the relevant facts and circumstances. Amounts classified as temporarily restricted are subject to donor-



imposed purpose or time restrictions which precluded us from expending such amounts or recognizing such amounts as unrestricted as of June 30, 2012.

16. The Organization has a reasonable basis for allocation of functional expenses.
17. The Organization is not subject to the requirements of OMB Circular A-133 as it did not expend more than \$500,000 in federal awards during the year ended June 30, 2012.

Further, we confirm that we are responsible for the fair presentation in the financial statements of the balance sheet, changes in net assets, and cash flows in conformity with U.S. generally accepted accounting principles. We are also responsible for establishing and maintaining effective internal control over financial reporting.

Very truly yours,

WonderWork, Inc.



Brian Mullaney
Founder & CEO



Hana Fuchs/CFO
CFO

TIME magazine named WonderWork one of "10 Ideas That Can Change The World."

420 Fifth Avenue, New York, NY 10018 Tel: 212 / 20 1955 WonderWork.org

WON-EX 042020



February 20, 2014

KPMG LLP
345 Park Avenue
New York, NY 10154

Ladies and Gentlemen:

We are providing this letter in connection with your audit of the balance sheet of WonderWork, Inc. (the Organization) as of June 30, 2013, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements for the purpose of expressing an opinion as to whether these financial statements present fairly, in all material respects, the financial position of the Organization, and the changes in its net assets and its cash flows in conformity with U.S. generally accepted accounting principles.

Certain representations in this letter are described as being limited to matters that are material. Items are considered material, regardless of size, if they involve an omission or misstatement of accounting information that, in the light of surrounding circumstances, makes it probable that the judgment of a reasonable person relying on the information would be changed or influenced by the omission or misstatement.

We confirm, to the best of our knowledge and belief, having made such inquiries as we considered necessary for the purpose of appropriately informing ourselves, as of February 20, 2014, the following representations made to you during your audits:

1. We have fulfilled our responsibilities, as set out in the terms of the audit engagement letter dated June 4, 2013, for the preparation and fair presentation of the financial statements in accordance with U.S. generally accepted accounting principles.
2. We have made available to you:
 - a. All records, documentation, and information that is relevant to the preparation and fair presentation of the financial statements.

TIME magazine named WonderWork one of "10 Ideas That Can Change The World."

320 Fifth Avenue, New York, NY 10018 Tel: 212.729.1855 WonderWork.org

WON-EX 042021

- b. Additional information that you have requested from us for the purpose of the audit.
 - c. Unrestricted access and the full cooperation of personnel within the entity from whom you determined it necessary to obtain audit evidence.
 - d. All minutes of meetings of the Board of Directors and committees of the Board of Directors, or summaries of actions of recent meetings for which minutes have not yet been prepared.
3. Except as disclosed to you in writing, there have been no communications from regulatory agencies, employees, or others concerning investigations or allegations of noncompliance with laws and regulations in any jurisdiction, deficiencies in financial reporting practices, or other matters that could have a material adverse effect on the financial statements.
4. There are no:
 - a. Violations or possible violations of laws or regulations, whose effects should be considered for disclosure in the financial statements or as a basis for recording a loss contingency.
 - b. Unasserted claims or assessments that our lawyer has advised us are probable of assertion and must be disclosed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 450, *Contingencies*.
 - c. Other liabilities or gain or loss contingencies that are required to be accrued or disclosed by FASB ASC 450, *Contingencies*.
 - d. Material transactions that have not been properly recorded in the accounting records underlying the financial statements.
 - e. Events that have occurred subsequent to the balance sheet date and through the date of this letter that would require adjustment to or disclosure in the financial statements.
5. All known actual or possible litigation and claims have been accounted for and disclosed in accordance with ASC Topic 450, *Contingencies*.
6. There are no uncorrected financial statement misstatements.

7. We acknowledge our responsibility for preventing and detecting fraud, including the design and implementation of programs and controls to prevent and detect fraud; for adopting sound accounting policies; and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statements and to provide reasonable assurance against the possibility of misstatements that are material to the financial statements whether due to error or fraud.
8. There are no deficiencies, significant deficiencies, or material weaknesses in the design or operation of internal control over financial reporting of which we are aware, which could adversely affect the Organization's ability to initiate, authorize, record, process, or report financial data. We have applied the definitions of a "significant deficiency" and a "material weakness" in accordance with the definitions in AU-C Section 265, Communicating Internal Control Related Matters Identified in an Audit.
9. We have no knowledge of any fraud or suspected fraud affecting the entity involving:
 - a. Management
 - b. Employees who have significant roles in internal control over financial reporting, or
 - c. Others where the fraud could have a material effect on the financial statements.
10. We have no knowledge of any allegations of fraud or suspected fraud affecting the entity received in communications from employees, former employees, regulators, or others.
11. The Organization has no plans or intentions that may materially affect the carrying value or classification of assets and liabilities.
12. We have no knowledge of any officer or director of the Organization, or any other person acting under the direction thereof, having taken any action to fraudulently influence, coerce, manipulate, or mislead you during your audit.
13. The following have been properly recorded or disclosed in the financial statements, if applicable:

- a. Related party transactions including sales, purchases, loans, transfers, leasing arrangements, guarantees, ongoing contractual commitments, and amounts receivable from or payable to related parties.
- b. Guarantees, whether written or oral, under which the Organization is contingently liable, including guarantee contracts and indemnification agreements pursuant to FASB ASC 460, *Guarantees*.
- c. Significant estimates and material concentrations known to management that are required to be disclosed in accordance with FASB ASC 275, *Risks and Uncertainties*.

Significant estimates are estimates at the balance sheet date, which could change materially within the next year. Concentrations refer to volumes of business, revenues, available sources of supply, or markets or geographic areas for which it is reasonably possible that events could occur which would significantly disrupt normal finances within the next year.

- 14. The Organization has satisfactory title to all owned assets, and there are no liens or encumbrances on such assets, nor has any asset been pledged as collateral.
- 15. Management is responsible for compliance with the laws, regulations, donor restrictions, and provisions of contracts and grant agreements applicable to Organization. Management has identified and disclosed to you all laws, regulations, donor restrictions, and provisions of contracts and grant agreements that have a direct and material effect on the determination of financial statement amounts.
- 16. We are responsible for making the fair value measurements and disclosures included in the financial statements in accordance with FASB ASC 820, *Fair Value Measurements and Disclosures*, including determining the fair value of assets and liabilities for which there has been a significant decrease in the volume and level of activity in relation to the normal market activity for those assets or liabilities (or similar assets or liabilities) or for which transactions are deemed not orderly. As part of fulfilling this responsibility, we have established an accounting and financial reporting process for determining the fair value measurements and disclosures, in accordance with the fair value techniques included in FASB ASC 820, considered the appropriateness of valuation techniques, including circumstances in which a practical expedient may be used to estimate fair value, adequately supported any significant assumptions used, and ensured that the presentation and disclosure of the fair value measurements are in accordance with generally accepted accounting principles including the disclosure requirements of FASB ASC 820. We

believe the assumptions and techniques used by us, including those used by specialists engaged by us, are in accordance with the definition of fair value in FASB ASC 820 and the disclosures adequately describe the level of the inputs used in the fair value measurement, in accordance with the fair value hierarchy in FASB ASC 820.

17. The Organization is responsible for determining the fair value of financial instruments as required by FASB ASC 825, *Financial Instruments*. The amounts disclosed represent the Organization's best estimate of fair value of financial instruments required to be disclosed under the FASB ASC 825, *Financial Instruments*. The Organization also has disclosed the methods and significant assumptions used to estimate the fair value of financial instruments and any changes to those methods and significant assumptions, if any, as required by FASB ASC 825.
18. The Organization has been recognized as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code of 1986 as an organization described in Section 501(c)(3) of the Code, as evidenced by our determination letter dated September 11, 2012, a copy of which has been furnished to you. Since the date of our determination letter, no changes have occurred in the organization or operation of the Organization that would affect our tax exempt status. Based on our determination letter, we have been classified as a public charity under Section 509(a) of the Internal Revenue Code, and since the date of our determination letter, no changes have occurred in the organization or its operations that would change this classification. Provision has been made, where material, for any federal, state or local income, excise, employment, property, sales and use, or other tax liability.
19. The Organization has classified net assets as unrestricted, temporarily restricted or permanently restricted based on our assessment of the donor's intention, as specified in original donor correspondence where available. Where not available, we used other corroborating evidential matter including minutes of the Board, accounting records and financial statements. To the extent that we were unable to review original donor correspondence to determine the amount of the original gift and donor additions, our determination of such amount was based on our best estimate considering the relevant facts and circumstances. Amounts classified as temporarily restricted are subject to donor-imposed purpose or time restrictions which precluded us from expending such amounts or recognizing such amounts as unrestricted as of June 30, 2013.
20. The Organization has a reasonable basis for allocation of functional expenses.
21. The Organization is not subject to the requirements of OMB Circular A-133 as it did not expend more than \$500,000 in federal awards during the year ended June 30, 2013.

Further, we confirm that we are responsible for the fair presentation in the financial statements of the balance sheet, changes in net assets, and cash flows in conformity with U.S. generally accepted accounting principles. We are also responsible for establishing and maintaining effective internal control over financial reporting.

Very truly yours,

WonderWork, Inc.

A handwritten signature in dark ink, appearing to read "Brian Mullaney", written over a horizontal line.

Brian Mullaney
Founder and CEO

A handwritten signature in dark ink, appearing to read "Hana Fuchs", written over a horizontal line.

Hana Fuchs
CFO

MULLANEY
EXHIBIT 52

Miracle surgeries for children.

w n e
w r

May 7, 2015

KPMG LLP
345 Park Avenue
New York, New York 10154

Ladies and Gentlemen:

We are providing this letter in connection with your audit of the balance sheet of WonderWork, Inc. (the Organization) as of June 30, 2014, the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements for the purpose of expressing an opinion as to whether these financial statements present fairly, in all material respects, the financial position, changes in net assets, and cash flows of the Organization in conformity with U.S. generally accepted accounting principles.

Certain representations in this letter are described as being limited to matters that are material. Items are considered material, regardless of size, if they involve an omission or misstatement of accounting information that, in the light of surrounding circumstances, makes it probable that the judgment of a reasonable person relying on the information would be changed or influenced by the omission or misstatement.

We confirm, to the best of our knowledge and belief, having made such inquiries as we considered necessary for the purposes of appropriately informing ourselves, as of May 7, 2015, the following representations made to you during your audits:

1. We have fulfilled our responsibilities, as set out in terms of the audit engagement letter dated October 20, 2014, for the preparation and fair presentation of the financial statements in accordance with U.S. generally accepted accounting principles.
2. We have made available to you:

TIME magazine named WonderWork one of "10 Ideas That Can Change The World."
420 Fifth Avenue, New York, NY 10018 Tel: 212.729.1855 WonderWork.org

EXHIBIT -52

Brian Mullaney

8/17/17

S. Anelle Santos, RPR, CSR

TransPerfect Legal

WON-EX 042027



- a. All records, documentation, and information that is relevant to the preparation and fair presentation of the financial statement.
 - b. Additional information that you have requested from us for the purpose of the audit.
 - c. Unrestricted access and the full cooperation of personnel within the entity from whom you determined it necessary to obtain audit evidence.
 - d. All minutes of meetings of the Board of Directors and committees of the Board of Directors, or summaries of actions of recent meetings for which minutes have not yet been prepared.
3. Except as disclosed to you in writing, there have been no:
- a. Circumstances that have resulted in communications from the Organization's external legal counsel to the Organization reporting evidence of a material violation of securities law or breach of fiduciary duty, or similar violation by the Organization or any agent thereof.
 - b. Communications from regulatory agencies, governmental representatives, employees, or others concerning investigations or allegations of noncompliance with laws and regulations in any jurisdiction, deficiencies in financial reporting practices, or other matters that could have a material adverse effect on the financial statements.
 - c. False statements affecting the Organization's financial statements made to the Organization's internal auditors, or other auditors who have audited entities under our control upon whose work you may be relying in connection with your audits.
4. There are no:
- a. Violations or possible violations of laws or regulations, in any jurisdiction, whose effects should be considered for disclosure in the financial statements or as a basis for recording a loss contingency.
 - b. Unasserted claims or assessments that our lawyer has advised us are probable of assertion and must be disclosed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 450, *Contingencies*.
 - c. *Other liabilities or gain or loss contingencies that are required to be accrued or disclosed by ASC Topic 450, Contingencies.*



- d. Material transactions that have not been properly recorded in the accounting records underlying the financial statements.
 - e. Events that have occurred subsequent to the balance sheet date and through the date of this letter that would require adjustment to or disclosure in the financial statements.
5. All known actual or possible litigation and claims have been accounted for and disclosed in accordance with ASC Topic 450, *Contingencies*.
6. There are no uncorrected financial statement misstatements.
7. We acknowledge our responsibility for the design, implementation and maintenance of programs and controls to prevent, and detect fraud; for adopting sound accounting policies; and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statements and to provide reasonable assurance against the possibility of misstatements that are material to the financial statements whether due to error or fraud. We understand that the term "fraud" includes misstatements arising from fraudulent financial reporting and misstatements arising from misappropriation of assets.
8. There are no deficiencies, significant deficiencies, or material weaknesses in the design or operation of internal control over financial reporting of which we are aware, which could adversely affect the Organization's ability to initiate, authorize, record, process, or report financial data. We have applied the definitions of a "significant deficiency" and a "material weakness" in accordance with the definitions in AU-C Section 265, *Communicating Internal Control Related Matters Identified in an Audit*.
9. We have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.
10. We have no knowledge of any fraud or suspected fraud affecting the entity's financial statements involving:
 - a. Management
 - b. Employees who have significant roles in internal control over financial reporting, or
 - c. Others where the fraud could have a material effect on the financial statements.
11. We have no knowledge of any allegations of fraud or suspected fraud affecting the entity's financial statements received in communications from employees, former employees, regulators, or others.



12. The Organization has no plans or intentions that may materially affect the carrying value or classification of assets and liabilities.
13. We have no knowledge of any officer or director of the Organization, or any other person acting under the direction thereof, having taken any action to fraudulently influence, coerce, manipulate, or mislead you during your audit.
14. The following have been properly recorded or disclosed in the financial statements if applicable:
 - a. Related party relationships and transactions, of which we are aware, in accordance with the requirements of U.S. generally accepted accounting principles, including sales, purchases, loans, transfers, leasing arrangements, guarantees, ongoing contractual commitments, and amounts receivable from or payable to related parties. Related party transactions do not involve undisclosed side agreements.
 - b. Guarantees, whether written or oral, under which the Organization is contingently liable, including guarantee contracts and indemnification agreements pursuant to FASB ASC 460, *Guarantees*.
 - c. Significant estimates and material concentrations known to management that are required to be disclosed in accordance with FASB ASC Topic 275, *Risks and Uncertainties*.

Significant estimates are estimates at the balance sheet date, which could change materially within the next year. Concentrations refer to volumes of business, revenues, available sources of supply, or markets or geographic areas for which it is reasonably possible that events could occur which would significantly disrupt normal finances within the next year.
15. The Organization has satisfactory title to all owned assets, and there are no liens or encumbrances on such assets, nor has any asset been pledged as collateral.
16. Management is responsible for compliance with the laws, regulations, donor restrictions, and provisions of contracts and grant agreements applicable to the Organization. Management has identified and disclosed to you all laws, regulations, donor restrictions, and provisions of contracts and grant agreements that have a direct and material effect on the determination of financial statement amounts.
17. The Organization has complied with all aspects of laws, regulations, contractual agreements, grants, and donor restrictions that may affect the financial statements, including noncompliance.



18. We are responsible for making the fair value measurements and disclosures included in the financial statements in accordance with FASB ASC Topic 820, *Fair Value Measurements*, including determining the fair value of assets and liabilities for which there has been a significant decrease in the volume and level of activity in relation to the normal market activity for those assets or liabilities (or similar assets or liabilities) or for which transactions are deemed not orderly. As part of fulfilling this responsibility, we have established an accounting and financial reporting process for determining the fair value measurements and disclosures, in accordance with the fair value techniques included in ASC Topic 820, considered the appropriateness of valuation techniques [including circumstances in which a practical expedient may be used to estimate fair value], adequately supported any significant assumptions used, and ensured that the presentation and disclosure of the fair value measurements are in accordance with U.S. generally accepted accounting principles including the disclosure requirements of ASC Topic 820. We believe the assumptions and techniques used by us, including those used by specialists engaged by us, are in accordance with the definition of fair value in ASC Topic 820 and the disclosures adequately describe the level of the inputs used in the fair value measurement, in accordance with the fair value hierarchy in ASC Topic 820.
19. The Organization is responsible for determining the fair value of financial instruments as required by FASB ASC Topic 825, *Financial Instruments*. The amounts disclosed represent the Organization's best estimate of fair value of financial instruments required to be disclosed under the ASC Topic 825. The Organization also has disclosed the methods and significant assumptions used to estimate the fair value of financial instruments and any changes to those methods and significant assumptions, if any, as required by ASC Topic 825.
20. The Organization has been recognized as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code of 1986 as an organization described in Section 501(c)(3) of the Code, as evidenced by our determination letter dated September 11, 2012, a copy of which has been furnished to you. Since the date of our determination letter, no changes have occurred in the organization or operation of the Organization that would affect our tax-exempt status. Based on our determination letter, we have been classified as a public charity under Section 509(a) of the Internal Revenue Code, and since the date of our determination letter, no changes have occurred in the organization or its operations that would change this classification. Provision has been made, where material, for any federal, state, or local income, excise, employment, property, sales and use, or other tax liability.
21. The Organization notes that an appropriate accrual, or lack thereof, for any Help Me See legal exposure has been booked in the financials as of June 30, 2014.
22. The Organization has a reasonable basis for allocation of functional expenses.



23. The Organization has a reasonable basis for determining estimates associated with in-kind contributions and has followed that basis at June 30, 2014.
24. The Organization confirms that the following 2014 contributions have no restrictions and thus are properly classified as unrestricted: [REDACTED]
25. The Organization is not subject to the requirements of OMB Circular A-133 as it did not expend more than \$500,000 in federal awards during the year ended June 30, 2014.

Further, we confirm that we are responsible for the fair presentation in the financial statements of financial position, changes in net assets and cash flows, and the related notes in conformity with U.S. generally accepted accounting principles.

Very truly yours,

WonderWork, Inc.



Brian Mullaney

Founder & CEO



Hana Fuchs

CFO

Miracle surgeries for children.



May 12, 2016

KPMG LLP
345 Park Avenue
New York, New York 10154

Ladies and Gentlemen:

We are providing this letter in connection with your audit of the balance sheet of Wonderwork, Inc. (the Organization) as of June 30, 2015, the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements for the purpose of expressing an opinion as to whether these financial statements present fairly, in all material respects, the financial position, changes in net assets, and cash flows of the Organization in accordance with U.S. generally accepted accounting principles.

Certain representations in this letter are described as being limited to matters that are material. Items are considered material, regardless of size, if they involve an omission or misstatement of accounting information that, in the light of surrounding circumstances, makes it probable that the judgment of a reasonable person relying on the information would be changed or influenced by the omission or misstatement.

We confirm, to the best of our knowledge and belief, having made such inquiries as we considered necessary for the purposes of appropriately informing ourselves, as of May 12, 2016, the following representations made to you during your audit:

1. We have fulfilled our responsibilities, as set out in terms of the audit engagement letter dated October 28, 2015, for the preparation and fair presentation of the financial statements in accordance with U.S. generally accepted accounting principles.
2. We have made available to you:
 - a. All records, documentation, and information that is relevant to the preparation and fair presentation of the financial statement.

WON-EX 042033



- b. Additional information that you have requested from us for the purpose of the audit.
 - c. Unrestricted access and the full cooperation of personnel within the entity from whom you determined it necessary to obtain audit evidence.
 - d. All minutes of meetings of the Board of Directors and committees of the Board of Directors, or summaries of actions of recent meetings for which minutes have not yet been prepared.
3. There have been no:
- a. Circumstances that have resulted in communications from the Organization's external legal counsel to the Organization reporting evidence of a material violation of securities law or breach of fiduciary duty, or similar violation by the Organization or any agent thereof.
 - b. Communications from regulatory agencies, governmental representatives, employees, or others concerning investigations or allegations of noncompliance with laws and regulations in any jurisdiction, deficiencies in financial reporting practices, or other matters that could have a material adverse effect on the financial statements.
 - c. False statements affecting the Organization's financial statements made to the Organization's internal auditors, or other auditors who have audited entities under our control upon whose work you may be relying in connection with your audit.
4. There are no:
- a. Violations or possible violations of laws or regulations, in any jurisdiction, whose effects should be considered for disclosure in the financial statements or as a basis for recording a loss contingency.
 - b. Unasserted claims or assessments that our lawyers have advised us are probable of assertion and must be disclosed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 450, *Contingencies*.
 - c. Other liabilities or gain or loss contingencies that are required to be accrued or disclosed by ASC Topic 450, *Contingencies*.
 - d. Other obligations resulting from joint and several liability arrangements that are required to be accrued or disclosed by FASB ASU 2013-04, *Liabilities (Topic 405) – Obligations Resulting From Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed At the Reporting Date*.



- e. Material transactions that have not been properly recorded in the accounting records underlying the financial statements.
 - f. Events that have occurred subsequent to the balance sheet date and through the date of this letter that would require adjustment to or disclosure in the financial statements.
- 5. All known actual or possible litigation and claims have been accounted for and disclosed in accordance with ASC Topic 450, *Contingencies*.
- 6. There are no uncorrected financial statement misstatements.
- 7. We acknowledge our responsibility for the design, implementation and maintenance of programs and controls to prevent, and detect fraud; for adopting sound accounting policies; and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statements and to provide reasonable assurance against the possibility of misstatements that are material to the financial statements whether due to error or fraud. We understand that the term "fraud" includes misstatements arising from fraudulent financial reporting and misstatements arising from misappropriation of assets.
- 8. There are no deficiencies, significant deficiencies, or material weaknesses in the design or operation of internal control over financial reporting of which we are aware, which could adversely affect the Organization's ability to initiate, authorize, record, process, or report financial data. We have applied the definitions of a "significant deficiency" and a "material weakness" in accordance with the definitions in AU-C Section 265, *Communicating Internal Control Related Matters Identified in an Audit*.
- 9. We have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.
- 10. We have no knowledge of any fraud or suspected fraud affecting the entity's financial statements involving:
 - a. Management
 - b. Employees who have significant roles in internal control over financial reporting, or
 - c. Others where the fraud could have a material effect on the financial statements.



11. We have no knowledge of any allegations of fraud or suspected fraud affecting the entity's financial statements received in communications from employees, former employees, analysts, regulators, or others.
12. The Organization has no plans or intentions that may materially affect the carrying value or classification of assets and liabilities.
13. We have no knowledge of any officer or director of the Organization, or any other person acting under the direction thereof, having taken any action to fraudulently influence, coerce, manipulate, or mislead you during your audit.
14. The following have been properly recorded or disclosed in the financial statements:
 - a. Related party relationships and transactions, of which we are aware, in accordance with the requirements of U.S. generally accepted accounting principles, including sales, purchases, loans, transfers, leasing arrangements, guarantees, ongoing contractual commitments, and amounts receivable from or payable to related parties. Related party transactions do not involve undisclosed side agreements.
 - b. Guarantees, whether written or oral, under which the Organization is contingently liable, including guarantee contracts and indemnification agreements pursuant to FASB ASC 460, *Guarantees*.
 - c. Significant estimates and material concentrations known to management that are required to be disclosed in accordance with FASB ASC Topic 275, *Risks and Uncertainties*.

Significant estimates are estimates at the balance sheet date, which could change materially within the next year. Concentrations refer to volumes of business, revenues, available sources of supply, or markets or geographic areas for which it is reasonably possible that events could occur which would significantly disrupt normal finances within the next year.
 - d. All assets and liabilities under the Organization's control.
15. The Organization has satisfactory title to all owned assets, and there are no liens or encumbrances on such assets, nor has any asset been pledged as collateral.
16. Management is responsible for compliance with the laws, regulations, donor restrictions, and provisions of contracts and grant agreements applicable to the Organization. Management has identified and disclosed to you all laws, regulations, donor restrictions, and provisions of contracts



and grant agreements that have a direct and material effect on the determination of financial statement amounts.

17. The Organization has complied with all aspects of laws, regulations, contractual agreements, grants, and donor restrictions that may affect the financial statements, including noncompliance.
18. Receivables reported in the financial statements represent valid claims against debtors arising on or before the date of the balance sheet and have been appropriately reduced to their estimated net realizable value.
19. The Organization has appropriately grouped long-lived assets together for purposes of assessing impairment in accordance with FASB ASC Topic 360, Property, Plant, and Equipment. We have reviewed long-lived assets, including amortizable intangible assets, to be held and used for impairment whenever events or changes in circumstances have indicated that the carrying amount of the assets might not be recoverable. Provision has been made for any material adjustments to long-lived assets including amortizable intangible assets.
20. We are responsible for making the fair value measurements and disclosures included in the financial statements in accordance with FASB ASC Topic 820, Fair Value Measurements, including determining the fair value of assets and liabilities for which there has been a significant decrease in the volume and level of activity in relation to the normal market activity for those assets or liabilities (or similar assets or liabilities) or for which transactions are deemed not orderly. As part of fulfilling this responsibility, we have established an accounting and financial reporting process for determining the fair value measurements and disclosures, in accordance with the fair value techniques included in ASC Topic 820, considered the appropriateness of valuation techniques, adequately supported any significant assumptions used, and ensured that the presentation and disclosure of the fair value measurements are in accordance with U.S. generally accepted accounting principles including the disclosure requirements of ASC Topic 820. We believe the assumptions and techniques used by us, including those used by specialists engaged by us, are in accordance with the definition of fair value in ASC Topic 820 and the disclosures adequately describe the level of the inputs used in the fair value measurement, in accordance with the fair value hierarchy in ASC Topic 820.
21. The Organization is responsible for determining the fair value of financial instruments as required by FASB ASC Topic 825, Financial Instruments. The amounts disclosed represent the Organization's best estimate of fair value of financial instruments required to be disclosed under the ASC Topic 825. The Organization also has disclosed the methods and significant assumptions used to estimate the fair value of financial instruments and any changes to those methods and significant assumptions, if any, as required by ASC Topic 825.



22. The Company is in compliance with bond indentures or other debt agreements.
23. The Organization has been recognized as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code of 1986 as an organization described in Section 501(c)(3) of the Code, as evidenced by our determination letter dated September 11, 2012, a copy of which has been furnished to you. Since the date of our determination letter, no changes have occurred in the organization or operation of the Organization that would affect our tax-exempt status. Based on our determination letter, we have been classified as a public charity under Section 509(a) of the Internal Revenue Code, and since the date of our determination letter, no changes have occurred in the organization or its operations that would change this classification. Provision has been made, where material, for any federal, state, or local income, excise, employment, property, sales and use, or other tax liability.
24. The Organization has classified net assets as unrestricted, or temporarily restricted, based on our assessment of the donor's intention, as specified in original donor correspondence where available. Where not available, we used other corroborating evidential matter including minutes of the Board, accounting records, and financial statements. To the extent that we were unable to review original donor correspondence to determine the amount of the original gift and donor additions, our determination of such amount was based on our best estimate considering the relevant facts and circumstances. Amounts classified as temporarily restricted are subject to donor-imposed purpose or time restrictions which precluded us from expending such amounts or recognizing such amounts as unrestricted as of the balance sheet date.
25. The Organization has a reasonable basis for allocation of functional expenses.
26. The Organization is not subject to the requirements of OMB Circular A-133 as it did not expend more than \$500,000 in federal awards during the year ended June 30, 2015.
27. The Organization notes that an appropriate accrual, or lack thereof, for any Help Me See legal exposure has been booked in the financials as of June 30, 2015.
28. The Organization has a reasonable basis for determining estimates associated with in-kind contributions and has followed that basis at June 30, 2015.

Further, we confirm that we are responsible for the fair presentation in the financial statements of financial position, changes in net assets and cash flows, and the related notes in accordance with U.S. generally accepted accounting principles.




Very truly yours,

WonderWork, Inc.



Brian Mullaney
Founder & CEO



Hana Fuchs
CFO

MULLANEY
EXHIBIT 53

Fill in this information to identify the case:

Debtor WonderWork, Inc.
United States Bankruptcy Court for the: Southern District District of NY
(If known) 16-13607 (MKV) (State)

☐ Check if this is an amended filing

Official Form 206E/F

Schedule E/F: Creditors Who Have Unsecured Claims

12/15

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on Schedule A/B: Assets - Real and Personal Property (Official Form 206A/B) and on Schedule G: Executory Contracts and Unexpired Leases (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims

- Do any creditors have priority unsecured claims? (See 11 U.S.C. § 507).
☐ No. Go to Part 2.
☐ Yes. Go to line 2.
- List in alphabetical order all creditors who have unsecured claims that are entitled to priority in whole or in part. If the debtor has more than 3 creditors with priority unsecured claims, fill out and attach the Additional Page of Part 1.

| | Total claim | Priority amount |
|--|--|-----------------|
| 2.1 Priority creditor's name and mailing address | As of the petition filing date, the claim is: \$ _____ | \$ _____ |
| | Check all that apply. | |
| | <input type="checkbox"/> Contingent | |
| | <input type="checkbox"/> Unliquidated | |
| | <input type="checkbox"/> Disputed | |
| Date or dates debt was incurred | Basis for the claim: _____ | |
| Last 4 digits of account number | Is the claim subject to offset? | |
| | <input type="checkbox"/> No | |
| | <input type="checkbox"/> Yes | |
| Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (____) | | |

| | | |
|--|--|----------|
| 2.2 Priority creditor's name and mailing address | As of the petition filing date, the claim is: \$ _____ | \$ _____ |
| | Check all that apply. | |
| | <input type="checkbox"/> Contingent | |
| | <input type="checkbox"/> Unliquidated | |
| | <input type="checkbox"/> Disputed | |
| Date or dates debt was incurred | Basis for the claim: _____ | |
| Last 4 digits of account number | Is the claim subject to offset? | |
| | <input type="checkbox"/> No | |
| | <input type="checkbox"/> Yes | |
| Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (____) | | |

| | | |
|--|--|----------|
| 2.3 Priority creditor's name and mailing address | As of the petition filing date, the claim is: \$ _____ | \$ _____ |
| | Check all that apply. | |
| | <input type="checkbox"/> Contingent | |
| | <input type="checkbox"/> Unliquidated | |
| | <input type="checkbox"/> Disputed | |
| Date or dates debt was incurred | Basis for the claim: _____ | |
| Last 4 digits of account number | Is the claim subject to offset? | |
| | <input type="checkbox"/> No | |
| | <input type="checkbox"/> Yes | |
| Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (____) | | |

EXHIBIT -53

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR

TransPerfect Legal

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

3. List in alphabetical order all of the creditors with nonpriority unsecured claims. If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

| | | Amount of claim |
|-----|--|--|
| 3.1 | Nonpriority creditor's name and mailing address <u>Action Mailers</u> <u>90 Commerce Drive</u> <u>Aston, PA 19014</u> Date or dates debt was incurred <u>Aug. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 18,839.14</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| 3.2 | Nonpriority creditor's name and mailing address <u>Bill & Ann Ziff Foundation</u> <u>350 Park Avenue, 4th Floor</u> <u>New York, NY 10022</u> Date or dates debt was incurred <u>May 2014</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 845,500.00</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Loan</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| 3.3 | Nonpriority creditor's name and mailing address <u>Brian Mullaney</u> <u>1 Sumner Lane</u> <u>Belmont, MA 02478</u> Date or dates debt was incurred <u>2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 641,320.07</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>2016 Salary/Unreimbursed expenses</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| 3.4 | Nonpriority creditor's name and mailing address <u>CDR Fundraising Group</u> <u>16900 Science Drive, Suite 210</u> <u>Bowie, MD 20715</u> Date or dates debt was incurred <u>Oct. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 48,750.00</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| 3.5 | Nonpriority creditor's name and mailing address <u>CENVEO</u> <u>Commercial Env. Products</u> <u>PO Box 802035, Chicago, IL 60680-2035</u> Date or dates debt was incurred <u>Oct. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 4,949.13</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| 3.6 | Nonpriority creditor's name and mailing address <u>Color Tree Group</u> <u>8000 Villa Park Drive</u> <u>Henrico, VA 23228-6500</u> Date or dates debt was incurred <u>Sept. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 21,719.22</u> Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

| | |
|--|---|
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Communications Corporation of America</u> <u>13195 Freedom Way</u> <u>Boston, VA 22713</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 6305.63</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed <input type="checkbox"/> Liquidated and neither contingent nor disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Copilevitz & Canter, LLC</u> <u>310 West 20th St., Suite 300</u> <u>Kansas City, MO 64108</u> Date or dates debt was incurred <u>Dec. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 1140.93</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Corporate Press, Inc.</u> <u>9700 Philadelphia Court</u> <u>Lanham, MD 20706</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 7,078.69</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Detter Family Foundation</u> <u>11519 Aerie Lane</u> <u>Naples, FL 34120</u> Date or dates debt was incurred <u>Aug. 2013</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 106,833.33</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Loan</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Development Resources, Inc.</u> <u>1820 N. Fort Meyer Drive, Suite 702</u> <u>Arlington, VA 22209</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | As of the petition filing date, the claim is: <u>\$ 10,000.00</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

| | |
|--|--|
| <p>3. Nonpriority creditor's name and mailing address <u>Direct Mail Processors, Inc.</u> <u>1150 Conrad Ct.</u> <u>Hagerstown, MD 21740</u> Date or dates debt was incurred <u>Sept. 2016</u> Last 4 digits of account number _____</p> | <p>As of the petition filing date, the claim is: <u>\$ 11,200.96</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed <input type="checkbox"/> Liquidated and neither contingent nor disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <p>3. Nonpriority creditor's name and mailing address <u>DMI Data Management, Inc.</u> <u>PO Box 846</u> <u>Stoneville, NC 27048</u> Date or dates debt was incurred <u>Dec. 2016</u> Last 4 digits of account number _____</p> | <p>As of the petition filing date, the claim is: <u>\$ 4997.49</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <p>3. Nonpriority creditor's name and mailing address <u>Hana Fuchs</u> <u>60 Riverside Drive, Apt. 7F</u> <u>New York, NY 10024</u> Date or dates debt was incurred <u>2016</u> Last 4 digits of account number _____</p> | <p>As of the petition filing date, the claim is: <u>\$ 8881.02</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Unreimbursed expenses</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <p>3. Nonpriority creditor's name and mailing address <u>HelpMeSee, Inc.</u> <u>20 West 36th St., Fl. 4</u> <u>New York, NY 10018</u> Date or dates debt was incurred <u>2016</u> Last 4 digits of account number _____</p> | <p>As of the petition filing date, the claim is: <u>\$ 16,059,833.50</u> <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: _____ Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <p>3. Nonpriority creditor's name and mailing address <u>IDMI</u> <u>490 White Pond Drive</u> <u>Akron, OH 44320</u> Date or dates debt was incurred <u>Oct. 2016</u> Last 4 digits of account number _____</p> | <p>As of the petition filing date, the claim is: <u>\$ 1628.52</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

3. Nonpriority creditor's name and mailing address
Joseph Mullaney

512 River Road
Westport, MA 02790

Date or dates debt was incurred

Aug. 2013

Last 4 digits of account number

As of the petition filing date, the claim is:
Check all that apply.

- ☐ Contingent
☐ Unliquidated
☐ Disputed
☐ Liquidated and neither contingent nor disputed

Basis for the claim: Loan

Is the claim subject to offset?

- ☒ No
☐ Yes

\$ 110,750.00

3. Nonpriority creditor's name and mailing address
Kaplan Kravet & Vogel P.C.

630 Third Avenue, 5th Floor
New York, NY 10017

Date or dates debt was incurred

Dec. 2016

Last 4 digits of account number

As of the petition filing date, the claim is:
Check all that apply.

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Services rendered

Is the claim subject to offset?

- ☒ No
☐ Yes

\$ 8259.03

3. Nonpriority creditor's name and mailing address
Koala Design

Attn: Mike Schell 1606 NE 1st St.
Fort Lauderdale, FL 33301

Date or dates debt was incurred

Dec. 2016

Last 4 digits of account number

As of the petition filing date, the claim is:
Check all that apply.

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Services rendered

Is the claim subject to offset?

- ☒ No
☐ Yes

\$ 8,500.00

3. Nonpriority creditor's name and mailing address
L&E Meridian

8000 Corporate Court
Springfield, VA 22153

Date or dates debt was incurred

Oct. 2016

Last 4 digits of account number

As of the petition filing date, the claim is:
Check all that apply.

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Services rendered

Is the claim subject to offset?

- ☒ No
☐ Yes

\$ 1359.48

3. Nonpriority creditor's name and mailing address
Log-On

520 Eighth Avenue, 14 Fl.
New York, NY 10018

Date or dates debt was incurred

Sept. 2016

Last 4 digits of account number

As of the petition filing date, the claim is:
Check all that apply.

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Services rendered

Is the claim subject to offset?

- ☒ No
☐ Yes

\$ 48,538.28

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

| | |
|---|--|
| <u>3.</u> Nonpriority creditor's name and mailing address <u>MDI Imaging and Mail</u> <u>21955 Cascades Parkway</u> <u>Sterling, VA 20166</u> Date or dates debt was incurred <u>Oct. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 4657.64</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed <input type="checkbox"/> Liquidated and neither contingent nor disputed</p> <p>Basis for the claim: <u>Services rendered</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Meadowlark Foundation</u> <u>PO Box 860</u> <u>Saratoga Springs, NY 12866</u> Date or dates debt was incurred <u>Jan. 2014</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 524,833.33</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Loan</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Nestle Pure Life Direct</u> <u>PO Box 856192</u> <u>Louisville, KY 40285</u> Date or dates debt was incurred <u>Dec. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 22.33</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Office supplies</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Nextiva</u> <u>8800 E Chaparral Rd. Ste 300</u> <u>Scottsdale, AZ 85260</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 527.56</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Utilities</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Resource One</u> <u>2900 E. Apache</u> <u>Tulsa, OK 74116</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 2165.80</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Services rendered</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

| | |
|--|--|
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Skyline Credit Ride, Inc.</u> <u>52-29 35th St.</u> <u>Long Island City, NY 11101</u> Date or dates debt was incurred <u>2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 43.05</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed <input type="checkbox"/> Liquidated and neither contingent nor disputed</p> <p>Basis for the claim: <u>Services rendered</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>The Holewinski Group</u> <u>253 Rainbow Drive #15398</u> <u>Livingston, TX 77399</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 120.00</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Services rendered</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>The Raphael & Diana Vinoly Foundation</u> <u>350 Fifth Avenue, 41 Fl.</u> <u>New York, NY 10118</u> Date or dates debt was incurred <u>Sept. 2013</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 60,083.33</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Loan</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Thompson Family Foundation</u> <u>c/o Kevin Maclay</u> <u>One Thomas Circle, NW, Ste. 1100, Washington, DC 20005</u> Date or dates debt was incurred <u>May 2013</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 7,979,166.67</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Loan</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |
| <u>3.</u> Nonpriority creditor's name and mailing address <u>Tri-State Envelope Corp.</u> <u>1 West 34 St., Suite 704</u> <u>New York NY 10001</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____ | <p>As of the petition filing date, the claim is: <u>\$ 2841.32</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: <u>Services rendered</u></p> <p>Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</p> |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 2: Additional Page

Copy this page only if more space is needed. Continue numbering the lines sequentially from the previous page. If no additional NONPRIORITY creditors exist, do not fill out or submit this page.

Amount of claim

| | |
|--|--|
| <div>3. Nonpriority creditor's name and mailing address <u>Union ID and Mail</u> <u>8516 Rainswood Drive</u> <u>Landover, MD 20785</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____</div> | <div>As of the petition filing date, the claim is: <u>\$ 3171.06</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed <input type="checkbox"/> Liquidated and neither contingent nor disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</div> |
| <div>3. Nonpriority creditor's name and mailing address <u>Valtim Marketing Solutions</u> <u>PO Box 809</u> <u>Forest, VA 24551</u> Date or dates debt was incurred <u>Oct. 2016</u> Last 4 digits of account number _____</div> | <div>As of the petition filing date, the claim is: <u>\$ 1967.73</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</div> |
| <div>3. Nonpriority creditor's name and mailing address <u>Wells Fargo Financial Leasing</u> <u>800 Walnut St., MAC N0005-055</u> <u>Des Moines, IA 50309</u> Date or dates debt was incurred <u>Dec. 2013</u> Last 4 digits of account number _____</div> | <div>As of the petition filing date, the claim is: <u>\$ 452.50</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Copier Lease</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</div> |
| <div>3. Nonpriority creditor's name and mailing address <u>XPO Logistics</u> <u>PO Box 2693</u> <u>New York, NY 10108</u> Date or dates debt was incurred <u>Nov. 2016</u> Last 4 digits of account number _____</div> | <div>As of the petition filing date, the claim is: <u>\$ 76.32</u> <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services rendered</u> Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</div> |
| <div>3. Nonpriority creditor's name and mailing address _____ _____ _____ Date or dates debt was incurred _____ Last 4 digits of account number _____</div> | <div>As of the petition filing date, the claim is: \$ _____ <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: _____ Is the claim subject to offset? <input type="checkbox"/> No <input type="checkbox"/> Yes</div> |

Debtor WonderWork, Inc.
Name

Case number (if known) 16-13607 (MKV)

Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims

5. Add the amounts of priority and nonpriority unsecured claims.

| | | Total of claim amounts |
|---|-------|---|
| 5a. Total claims from Part 1 | 5a. | \$ <u>0</u> |
| 5b. Total claims from Part 2 | 5b. + | \$ <u>26,556,513.06</u> |
| 5c. Total of Parts 1 and 2 Lines 5a + 5b = 5c. | 5c. | <div style="border: 1px solid black; padding: 2px;">\$ <u>26,556,513.06</u></div> |

MULLANEY
EXHIBIT 54

| | | | | | | | | | | | |
|---------------------|--------------|--------------|----------------------------------|-----------------------|--|-----------------|------------|--|----------|---------|--|
| Sep.14 | 0.00 | 39,583.33 | | | | bonus | 250,000.00 | see e-mail from JJ 10/21/14 | | | |
| bonus per 10/21/14 | | 250,000.00 | | | | Aug.14 | 39,583.33 | | | | |
| per e-mail 10/1/14 | | -1,000.00 | | | | Sep.14 | 39,583.33 | | | | |
| Oct.14 | 0.00 | 39,583.33 | | | | x Oct.14 | 38,583.33 | per e-mail 10/1/14 | 1,000.00 | | |
| per e-mail 10/21/14 | | -50,000.00 | | | | x 10/21/14email | 50,000.00 | 10/21/14email | | | |
| | 0.00 | 39,583.33 | | | | Nov.14 | 39,583.33 | | | | |
| Dec. 14 | 0.00 | 39,583.33 | 445,499.88 | | | Dec.14 | 39,583.33 | | | | |
| Calendar 2014 | \$475,000.00 | | | | | Jan. 15 | 39,583.33 | | | | |
| Jan. 15 | \$50,000.00 | -510,416.67 | | | | Jan.15 | 485,083.21 | | | | |
| 1/8/2015 | | -2,274.09 | holiday dinner | | | | -50,000.00 | payroll | | | |
| 2/9/2015 | | -1,300.00 | MAB dinner | | | | 435,083.21 | | | | |
| Feb.15 | 39,583.33 | \$431,508.12 | end of Jan. 15 | | | x 1/8/15 email | 2,274.09 | holiday dinner | | | |
| Feb.15 additional | 385,416.67 | | to bring calendar year to \$475k | | | x 2/9/15 email | 1,300.00 | MAB dinner | | | |
| Mar.15 | 0.00 | 39,583.33 | \$46,092.45 | balance as of Feb.15 | | | 431,509.12 | | | | |
| Apr.15 | 0.00 | 39,583.33 | | | | Feb. 14 | 39,583.33 | | | | |
| May.15 | 0.00 | 39,583.33 | -25,000.00 | april 2015 emails | | | -39,583.33 | paid 7/13/15 | | | |
| Jun.15 | 0.00 | 39,583.33 | -5,000.00 | 5/6/15 e-mail | | paid in Feb | 385,416.67 | to bring calendar 2015 to 475,000 | | | |
| FY15 | \$475,000.00 | \$204,425.77 | \$167,773.60 | balance as of 6/15/15 | | remaining | 46,092.45 | | | | |
| | | | | | | % of the | | | | | |
| | | | | | | end of Feb.15 | | | | | |
| Jul.15 | 0.00 | 39,583.33 | \$207,356.93 | | | Mar.15 | 39,583.33 | | | | |
| Aug.15 | 0.00 | 39,583.33 | \$248,940.26 | | | Apr.15 | 39,583.33 | | | | |
| Sep.15 | 0.00 | 39,583.33 | \$285,173.59 | | | | 125,259.11 | | | | |
| Oct.15 | 0.00 | 39,583.33 | \$322,696.18 | | | x | 15,000.00 | 4/20/15 per mb for writer | | | |
| Nov.15 | 0.00 | 39,583.33 | \$356,202.29 | | | | 3,000.00 | 4/20/15 per mb for Photoshop lessons | | | |
| Dec.15 | 0.00 | 39,583.33 | \$358,860.62 | | | | 116,259.11 | as of 4/20/15 | | | |
| Calendar 2015 | \$475,000.00 | | | | | x | 20,000.00 | e-mail 4/21/15 | | | |
| Jan.16 | \$0.00 | 39,583.33 | \$398,443.95 | | | May.15 | | | | | |
| Feb.16 | \$0.00 | 39,583.33 | \$538,027.28 | | | x | 130,842.44 | e-mail 5/6/15 \$-5,000 for camera equipment | | | |
| Mar.16 | \$0.00 | 39,583.33 | \$630,314.37 | | | x | 26,727.11 | e-mail 6/3/15 skyline deductions | | | |
| Apr.16 | \$0.00 | 39,583.33 | \$669,897.70 | | | June.15 | 39,583.33 | | | | |
| May.16 | \$0.00 | 39,583.33 | \$709,481.03 | | | | 167,773.60 | June Board 2015 meeting reduction of \$150k not included | | | |
| Jun.16 | \$475,000.00 | 39,583.33 | \$749,064.36 | | | July.15 | 39,583.33 | | | | |
| FY16 | \$475,000.00 | \$274,064.36 | | | | Aug.15 | 207,356.93 | | | | |
| | | | | | | | 39,583.33 | | | | |
| FY16 bonus per bod | \$0.00 | 250,000.00 | \$524,064.36 | | | | 246,940.26 | | | | |
| Jul.16 | \$0.00 | 39,583.33 | \$534,840.36 | | | Sep.15 | 3 | 3% | | | |
| Aug.16 | \$0.00 | 39,583.33 | \$570,793.06 | | | x | 13,500.00 | e-mail 9/23/15 | | | |
| Sep.16 | \$0.00 | 39,583.33 | \$596,664.08 | | | owed | 285,173.59 | Sep.15 | | | |
| Oct.16 | \$0.00 | 39,583.33 | \$62,613.46 | | | | 2,057.74 | e-mail 10.08.15 harvard club | | | |
| Nov.16 | \$0.00 | 39,583.33 | \$66,716.79 | | | Oct.15 | 39,583.33 | | | | |
| Dec.16 | \$0.00 | 39,583.33 | \$24,800.42 | 32,166.66 | | owed to date | 322,699.18 | Oct. 15 | | | |
| Calendar 2016 | \$475,000.00 | | | | | x Nov. 15 | 39,583.33 | writer on India trip | | | |
| Jan.17 | \$0.00 | 39,583.33 | 664,383.45 | | | | 39,583.33 | | | | |
| Feb.17 | \$0.00 | 39,583.33 | 703,866.78 | | | | 356,202.29 | Nov. 15 | | | |
| Mar.17 | \$0.00 | 39,583.33 | 748,550.11 | | | | 39,583.33 | Dec. 15 | | 475,000 | |
| Apr.17 | \$0.00 | 39,583.33 | 789,338.44 | | | | 358,860.62 | staff bonus email 11/23/15 | | 250,000 | |
| May.17 | \$0.00 | | | | | | 200,000.00 | bonus per 11/22/15 | | 725,000 | |
| Jun.17 | \$0.00 | | | | | Dec. 15 | | | | | |
| FY17 | \$0.00 | | | | | Jan. 16 | 39,583.33 | | | | |

WON07287

| NOTES | | | | | | | |
|-------|------------------------|------------|--|-----------------|--|--|--|
| 1 | personal reimbursement | -22,000.00 | e-mail BM 1/6/14 | | | | |
| 2 | 4/5/2014 | -30,000.00 | about 50% weekly travel FY14, FY15 | | | | |
| 3 | | -10,000.00 | annual [REDACTED] visits | | | | |
| 4 | 4/5/2014 | -38,000.00 | additional contribution | | | | |
| 5 | Oct. 14 | -1,000.00 | per e-mail 10/1/14 | | | | |
| 6 | 10/21/14email | -50,000.00 | 10/21/14email | | | | |
| 7 | 1/8/15 email | -2,274.09 | holiday dinner | | | | |
| 8 | 2/9/15 email | -1,300.00 | MAB dinner | | | | |
| 9 | | -6,000.00 | 4/20/15 per mb for writer | | | | |
| 10 | | -3,000.00 | 4/20/15 per mb for Photoshop lessons | | | | |
| 11 | | -20,000.00 | e-mail 4/21/15 June [REDACTED] trip | | | | |
| 12 | | -5,000.00 | e mail 5/6/15 \$-5,000 for camera equipment | | | | |
| 13 | | -2,652.17 | e-mail 6/3/15 skyline deductions | | | | |
| 14 | | -1,350.00 | e-mail 9/23/15 | | | | |
| 15 | | -2,057.74 | e-mail 10.08.15 harvard club | | | | |
| 16 | Nov. 15 | -6,080.22 | writer on India trip | | | | |
| 17 | | -36,925.00 | staff bonus email 11/23/15 | | | | |
| 18 | | -1,223.75 | golf balls | | | | |
| 19 | | -23,493.86 | langham bills for 2015 per amex 3/11/16 email | | | | |
| 20 | 3/11/2016 | -11,028.60 | amtrak for 2015 per amex | | | | |
| 21 | 3/11/2016 | -2,977.56 | other taxis for 2015 per amex | | | | |
| 22 | | -8,572.47 | 4 seasons 3/11/16 e-mail | 1/24/15-1/23/16 | | | |
| 23 | email 6/7/16 | -3,675.46 | 4 seasons 3/18-8/2/16 | | | | |
| 24 | email 6/7/16 | -2,975.36 | skyline deductions through 7/13/16 | | | | |
| 25 | email 7/31/16 | -13,742.29 | langham bills for 2016 per amex through July 31, 2016 | | | | |
| 26 | email 7/31/16 | -7,061.00 | amtrak bills for 2016 per amex through July 31, 2016 | | | | |
| 27 | email 7/31/16 | -1,353.22 | other misc taxis bills for 2016 per amex through July 31, 2016 | | | | |
| 28 | | -3,750.00 | 8/14/16 per mb additional Photoshop lessons | | | | |
| 29 | | -378.63 | July 2016 legal | | | | |
| 30 | email 9/8/16 | -12,423.33 | annual [REDACTED] visit July 2016 email 09/08/16 | | | | |
| 31 | e-mail 9/12/16 | -790.98 | trip to black pearl lodge | | | | |
| 32 | 9/28/2016 | -15,000.00 | healthcare (annual) | | | | |
| 33 | 10/19/2016 | -25,000.00 | trip to Bangladesh | | | | |
| 34 | 10/21/2016 | -3,613.95 | camera | | | | |
| 35 | 10/31/2016 | -5,000.00 | computer | email | | | |
| 36 | 10/31/2016 | -500.00 | az invites | email | | | |
| 37 | 12/4/2016 | -41,500.00 | bonus email bm 12/4/16 | | | | |

MULLANEY
EXHIBIT 55

| | | | | | | | |
|--|--|---|--|--|--|--|--|
| Void <input type="checkbox"/> | | a Employee's social security number [REDACTED] | | OMB No. 1545-0008 Q3J | | 000001 | |
| b Employer identification number (EIN) 27-4159217 | | | | 1 Wages, tips, other compensation 475000.00 | | 2 Federal income tax withheld 130870.00 | |
| c Employer's name, address, and ZIP code WONDERWORK INC 420 5TH AVE 27TH FLOOR NEW YORK, NY 10018 | | | | 3 Social security wages 110100.00 | | 4 Social security tax withheld 4624.20 | |
| | | | | 5 Medicare wages and tips 475000.00 | | 6 Medicare tax withheld 6887.50 | |
| | | | | 7 Social security tips | | 8 Allocated tips | |
| | | | | 9 [REDACTED] | | 10 Dependent care benefits | |
| d Control number 000001 RF/Q3J | | | | 11 Nonqualified plans | | 12a See instructions for box 12 | |
| e Employee's first name and initial Last name BRIAN F MULLANEY [REDACTED] | | | | 13 Statutory employee Retirement plan Third-party sick pay <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | | 12b | |
| | | | | 14 Other 28.00 VPD | | 12c | |
| | | | | | | 12d | |
| | | | | | | | |
| f Employee's address and ZIP code | | | | 15 State Employer's state ID number NY 27-4159217 | | 16 State wages, tips, etc. 475000.00 | |
| | | | | 17 State income tax 37613.10 | | 18 Local wages, tips, etc. | |
| | | | | | | 19 Local income tax | |
| | | | | | | 20 Locality name | |

Form **W-2** Wage and Tax Statement

2012

Department of the Treasury—Internal Revenue Service
For Privacy Act and Paperwork Reduction Act Notice, see separate instructions.

Copy D — For Employer.

EXHIBIT -55
Brian Mullaney
8/17/17
S. Anelle Santos, RPR, CSR
TransPerfect Legal

CONFIDENTIAL

WON 06398

| | | | | | | | |
|--|--|---|--|--|--|--|--|
| Void <input type="checkbox"/> | | a Employee's social security number [REDACTED] | | OMB No. 1545-0008 Q3J | | 000001 | |
| b Employer identification number (EIN) 27-4159217 | | | | 1 Wages, tips, other compensation 475000.00 | | 2 Federal income tax withheld 131176.62 | |
| c Employer's name, address, and ZIP code WONDERWORK INC 420 5TH AVE 27TH FLOOR NEW YORK, NY 10018 | | | | 3 Social security wages 113700.00 | | 4 Social security tax withheld 7049.40 | |
| | | | | 5 Medicare wages and tips 475000.00 | | 6 Medicare tax withheld 9362.50 | |
| | | | | 7 Social security tips | | 8 Allocated tips | |
| | | | | 9 [REDACTED] | | 10 Dependent care benefits | |
| d Control number 000001 RF/Q3J | | | | 11 Nonqualified plans | | 12a See instructions for box 12 | |
| e Employee's first name and Initial Last name Suff. BRIAN F MULLANEY [REDACTED] | | | | 13 Statutory employee Retirement plan Third-party sick pay <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | | 12b | |
| | | | | 14 Other 26.00 VPD | | 12c | |
| | | | | | | 12d | |
| | | | | | | | |
| f Employee's address and ZIP code | | | | | | | |
| 15 State Employer's state ID number NY 27-4159217 | | 16 State wages, tips, etc. 475000.00 | | 17 State income tax 33731.15 | | 18 Local wages, tips, etc. | |
| | | | | | | 19 Local income tax | |
| | | | | | | 20 Locality name | |

Form **W-2** Wage and Tax
Statement
Copy D — For Employer

2013

Department of the Treasury—Internal Revenue Service
For Privacy Act and Paperwork Reduction
Act Notice, see separate instructions.

| | | | | | | | |
|--|--|---|--|--|--|--|--|
| Void <input type="checkbox"/> | | a Employee's social security number [REDACTED] | | OMB No. 1545-0008 Q3J | | 000001 | |
| b Employer identification number (EIN) 27-4159217 | | | | 1 Wages, tips, other compensation 475000.00 | | 2 Federal income tax withheld 152353.22 | |
| c Employer's name, address, and ZIP code WONDERWORK INC 420 5TH AVE 27TH FLOOR NEW YORK, NY 10018 | | | | 3 Social security wages 117000.00 | | 4 Social security tax withheld 7254.00 | |
| | | | | 5 Medicare wages and tips 475000.00 | | 6 Medicare tax withheld 9362.50 | |
| | | | | 7 Social security tips | | 8 Allocated tips | |
| d Control number 000001 RF/Q3J | | | | 9 | | 10 Dependent care benefits | |
| e Employee's first name and initial Last name BRIAN F MULLANEY [REDACTED] | | | | 11 Nonqualified plans | | 12a See instructions for box 12 | |
| | | | | 13 Statutory employee Retirement plan Third-party sick pay <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | | 12b | |
| | | | | 14 Other 18.20 VPD | | 12c | |
| | | | | | | 12d | |
| f Employee's address and ZIP code | | | | | | | |
| 15 State Employer's state ID number NY 27-4159217 | | 16 State wages, tips, etc. 475000.00 | | 17 State income tax 38234.85 | | 18 Local wages, tips, etc. | |
| | | | | | | 19 Local income tax | |
| | | | | | | 20 Locality name | |

Form **W-2** Wage and Tax
Statement
Copy D — For Employer

2014

Department of the Treasury—Internal Revenue Service
For Privacy Act and Paperwork Reduction
Act Notice, see separate instructions.

CONFIDENTIAL

WON 06400

| | | | | | | | |
|---|--|---|--|--|--|--|--|
| Void <input type="checkbox"/> | | a Employee's social security number [REDACTED] | | OMB No. 1545-0008 Q3J | | 000001 | |
| b Employer identification number (EIN) 27-4159217 | | | | 1 Wages, tips, other compensation 451000.00 | | 2 Federal income tax withheld 132670.84 | |
| c Employer's name, address, and ZIP code WONDERWORK INC 420 5TH AVE 27TH FLOOR NEW YORK, NY 10018 | | | | 3 Social security wages 118500.00 | | 4 Social security tax withheld 7347.00 | |
| | | | | 5 Medicare wages and tips 475000.00 | | 6 Medicare tax withheld 9362.50 | |
| | | | | 7 Social security tips | | 8 Allocated tips | |
| d Control number 000001 RF/Q3J | | | | 9 [REDACTED] | | 10 Dependent care benefits | |
| e Employee's first name and Initial BRIAN F | | Last name MULLANEY | | 11 Nonqualified plans | | 12a See instructions for box 12 D 24000.00 | |
| f Employee's address and ZIP code [REDACTED] | | Suff. [REDACTED] | | 13 <input type="checkbox"/> Salary <input checked="" type="checkbox"/> Retirement plan <input type="checkbox"/> Third-party sick pay | | 12b | |
| | | | | 14 Other 7.80 VPD1 | | 12c | |
| | | | | | | 12d | |
| 15 State Employer's state ID number NY 27-4159217 | | 16 State wages, tips, etc. 451000.00 | | 17 State income tax 33986.75 | | 18 Local wages, tips, etc. | |
| | | | | | | 19 Local income tax | |
| | | | | | | 20 Locally imposed | |

Form **W-2** Wage and Tax Statement
Copy D — For Employer

2015

Department of the Treasury—Internal Revenue Service
For Privacy Act and Paperwork Reduction Act Notice, see separate instructions.

CONFIDENTIAL

WON 06401

MULLANEY
EXHIBIT 56

Hana Fuchs

From: Brian Mullaney
Sent: Monday, January 06, 2014 4:11 PM
To: Hana Fuchs
Subject: Re: back pay

If it is okay with you, I'd like to deduct the \$22,000 from my impact loan. Thus, my loan is reduced to \$228,000.

Ok?

B.

Brian Mullaney
Co-Founder/CEO
WonderWork
420 Fifth Avenue, 27th Floor
New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org

From: Hana Fuchs <hana@wonderwork.org>
Date: Monday, January 6, 2014 4:08 PM
To: brian mullaney <brian@wonderwork.org>
Subject: RE: back pay

I've attached the spreadsheet we keep based on your expenses above and what WW owes for Oct., Nov. and Dec. 13 which does not include the Impact Loan.
Let me now if you have any questions.
Thanks Hana

| | Oct.13 | Nov.13 | Dec.13 | Total 2013 |
|----------------------------------|------------|-----------|-----------|------------|
| | 39,583.33 | | | |
| paid in Oct. | 22,250.07 | | | |
| owed to bm | 17,333.26 | 39,583.33 | 39,583.33 | |
| less misc. per Karen spreadsheet | -2,106.63 | | | |
| less [REDACTED] | -3,797.43 | | | |
| 11/5/2013 less dinner 4 Seasons | -15,000.00 | | | |
| 12/9/2013 holiday dinner | -1,009.00 | | | |
| | -4,579.80 | 39,583.33 | 39,583.33 | 74,586.86 |

From: Brian Mullaney
Sent: Monday, January 06, 2014 3:41 PM

EXHIBIT -56

Brian Mullaney

8/17/17

S. Arielle Santos, RPR, CSR
TransPerfect Legal

To: Hana Fuchs
Subject: back pay

Hi Hana,

Can you please add any extra pay from 2013 that I did not take with my January pay?

This of course does not include the \$250,000 bonus which I loaned to WonderWork as part of our impact loan. I should ask Karen to fill out some paperwork for me for this. I am not going to take any interest and I may forgive some or all of it.

Thank you,

Brian

Brian Mullaney
Co-Founder/CEO
WonderWork
420 Fifth Avenue, 27th Floor
New York, NY 10018
tel: 212.729.1855
cell: 917.902.7550
email: brian@wonderwork.org
www.WonderWork.org